(XNET) Announces An Up to US$20 million Share Repurchase Program

SHENZHEN, China, Dec. 22, 2014  — Xunlei Limited (“Xunlei” or the “Company”) (Nasdaq: XNET), China’s leading provider of acceleration products and services, today announced that its board of directors has approved an up to US$20 million share repurchase program to repurchase Xunlei’s issued and outstanding shares.

“Our management team and Board of Directors have a strong conviction in our core business and long-term prospects. We believe repurchasing our shares is a prudent use of our cash and are pleased that our financial position also allows us to start building Xunlei’s track record of returning value to shareholders,” Mr. Sean Zou, Chairman and Chief Executive Officer of Xunlei, commented.

Xunlei’s share repurchases may be made in accordance with applicable laws and regulations through open market transactions, privately negotiated transactions or other legally permissible means as determined by Xunlei’s management, including through Rule 10b5-1 share repurchase plans. Xunlei expects to implement this share repurchase program over the next 12 months. The timing and extent of any purchases will depend upon market conditions, the trading price of its ADSs and other factors. Xunlei’s Board of Directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size accordingly.

The share repurchase program will be funded using Xunlei’s existing cash balance. As of 30 September, 2014, Xunlei had cash, cash equivalents and short-term investments of approximately US$433 million.

About Xunlei

Xunlei Limited (“Xunlei”) is one of the top 10 largest Chinese Internet companies, with an average of approximately 309 million monthly unique visitors as at September of 2014, according to iResearch. Xunlei is the No. 1 acceleration product provider in China as measured by market share. Xunlei operates a powerful Internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its core products and services, Xunlei Accelerator and the cloud acceleration subscription services. Xunlei is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones and to living rooms through TV coverage. Benefitting from the large user base accumulated by Xunlei Accelerator, Xunlei has further developed various value-added services, including Xunlei Kankan, online game and pay per view, to meet a fuller spectrum of its users’ digital media content access and consumption needs.

Safe Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward- looking statements by terminology such as “will,” “expects,” “believes,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the management’s quotations regarding the share repurchase program contain forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. Forward-looking statements involve inherent risks and uncertainties, including but not limited to: the Company’s ability to continue to innovate and provide attractive products and services to retain and grow its user base; the Company’s ability to keep up with technological developments and users’ changing demands in the Internet industry; the Company’s ability to convert its users into subscribers of its premium services; and the Company’s ability to deal with existing and potential copyright infringement claims and other related claims; and the Company’s ability to compete effectively. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. Further information regarding risks and uncertainties faced by the Company is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of the press release, and the Company undertakes no obligation to update any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

IR Contact:

Mr. Yuanyuan Chen (English and Chinese)
Investor Relations Director
Mobile +86 139-2337-7882 or +852 6954-7509 in Shenzhen
chenyuanyuan@xunlei.com

PR Contact:

Fleishman-Hillard
Email: hkg.xnet@fleishman.com

(CFRX) FDA Approval to Initiate Clinical Trials of CF-301 for MRSA

(CNET) Online Holdings Signs Strategic Partnership Agreement With MediaFun

BEIJING, Dec. 22, 2014  — ChinaNet Online Holdings, Inc. (Nasdaq:CNET) (“ChinaNet” or the “Company”), a leading B2B (business to business) Internet technology company providing online-to-offline (O2O) sales channel expansion services for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking services for entrepreneurs in the People’s Republic of China, announced today that the Company has signed a long-term strategic partnership agreement with MediaFun Creative Co. (MediaFun), a total solution service platform for cloud print services company based in Taiwan.

MediaFun’s creative printing services platform allows non-professional users to complete the professional design process in a few minutes, and independently modify and print work by customers. The Company’s main products include school graduation memento books, photobooks and personalized photo gifts such as photo albums, cards and other merchandise.

MediaFun’s growth is being fueled by the substantial graduate market in Taiwan, which accounts for approximately 5% of the total population every year. Cloud printing is also being supported by the Taiwan government in an effort to update the traditional print industry. MediaFun sees this partnership opportunity as the beginning of a long-term growth strategy into the expanding China market. MediaFun currently has approximately 250 customers in Taiwan.

Under the terms of the agreement, ChinaNet will leverage its experience and advantages in the SME industry in China to help MediaFun expand its B2b2c market sales marketing to multiple of cities through mobile and internet. MediaFun will in turn share its cloud printing technology to help individuals utilize their print services throughout the China market. The two companies intend to share in profits and commissions under a joint venture agreement.

On December 22, 2014, a signing ceremony was held for the two companies at the Taiwan Trade Center of Beijing.

“We are excited to undertake this new strategic partnership with MediaFun, who is revolutionizing the field of print services,” said George Chu, ChinaNet Online’s Chief Operating Officer. “This cooperative agreement continues our ongoing efforts to expand our marketing and related value-added services for our clients. We in turn look forward to utilizing our deep experience in franchising and the China market to help MediaFun expand its business opportunities. This is a milestone for our company to help an overseas SME to efficiently expand its sales channel in China through ChinaNet services and technology.”

About MediaFun Creative Co.

MediaFun Creative Co.,headquartered in Taiwan, is the first total solution service platform for cloud print services. Founded in 2006, focusing on the integration of prepress workflow, the cloud cultural and creative printing services platform it developed allows non-professional users to complete the professional design process in a few minutes, and independently modify and print work by customers. This service platform is widely used in all types of schools yearbook and personalized market in Taiwan. The main products are the school’s graduation memento book, photo book series, personalized photo gifts, such as photo albums, cards, and personalized merchandise. Taiwan’s Ministry of Economic Affairs approved the MediaFun as R & D subsidies unit; the company awarded several technical R & D subsidies, and selected the display manufacturers of Taiwan famous brand exhibition in 2014.

About ChinaNet Online Holdings, Inc.

The Company, a parent company of ChinaNet Online Media Group Ltd., incorporated in the BVI (“ChinaNet”), is a leading digital B2B (business to business) Internet technology company focusing on providing O2O sales channel expansion service for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking service for entrepreneurs in China. The Company, through certain contractual arrangements with operating companies in the PRC, provides Internet advertising and other services for Chinese SMEs via its portal websites, 28.com, Liansuo.com and Chuangye.com, TV commercials and program production via China-Net TV, and in-house LCD advertising on banking kiosks targeting Chinese banking patrons. Website: http://www.chinanet-online.com.

Safe Harbor

This release contains certain “forward-looking statements” relating to the business of ChinaNet Online Holdings, Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “estimates” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ChinaNet’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting ChinaNet will be those anticipated by ChinaNet. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ChinaNet undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT: MZ North America
         Ted Haberfield, President
         Direct: +1-760-755-2716
         Email: thaberfield@mzgroup.us
         Web: www.mzgroup.us

(SKYS) Announces Entry Into China Solar Market

HONG KONG, Dec. 22, 2014  — Sky Solar Holdings, Ltd. (Nasdaq:SKYS) (“Sky Solar” or the “Company”), a global renewable energy developer and independent power producer today announced its intention to enter the Chinese solar market. Sky Solar believes that the country is a high-priority growth opportunity due to its large size and rapidly growing renewable energy sector, as well as the Company’s own extensive knowledge of the market.

The Company intends to own fully operational solar assets, as well as build and transfer assets to external third parties which are mainly state-owned conglomerates and public companies. The Company has always planned to target selective provinces with large imbalances between power supply and demand, as well as the most attractive financial strength, based on the ability to make timely payments of feed-in-tariffs.

The Company’s board of directors approved the establishment of legal and operational entities to enter the China market, and authorized the Company’s management team to evaluate acquisition targets to build the operating assets in China. Among the targets under evaluation include solar park and EPC assets owned by private entities controlled by the Company’s Chairman, Mr. Weili Su, which own 165 MW of projects in operation and under construction and 4.9 GW of projects in various stages of development.

Pursuant to the Company’s Corporate Governance Guidelines, a majority of the Company’s directors, including all of the Company’s independent directors, must approve any acquisition of businesses, solar parks or other assets from related parties or independent third parties. All approvals are based on a myriad of factors including but not limited to IRR, technical specifications of the solar project (including sun irradiation hours, components and performance guarantees) and technical, financial and legal due diligence. The Company believes that these strong internal controls ensure that any related-party transaction will occur at a fair market price. In addition, under the Company’s Corporate Governance Guidelines, two-thirds of all shareholders must also approve certain purchases from related parties that are individually or in the aggregate over the last twelve months equivalent to 20% or more of the Company’s market capitalization.

The Company is also establishing a new business platform, to be named “Sky-Link”, for integrating supply-chain and industry data and analysis, and standardizing solar project quality control and monitoring. The Company will use these capabilities internally as well as offer the services to third parties for a fee. The Company is evaluating a potential acquisition of Changzhou Sky Solar New Energy Technology Co., Ltd. (“Changzhou Sky Solar New Energy Technology”) at fair market value by Sky-Link, in order to quickly enter the solar project quality control and monitoring business. Changzhou Sky Solar New Energy Technology is a well-established vendor of services including (i) PV materials, products and plants testing, (ii) project acceptance inspections, and (iii) solar project supervision. Changzhou Sky Solar New Energy Technology is a related entity controlled by the Company’s Chairman Mr. Su, and accordingly the acquisition would be need to be approved under the Company’s strict Corporate Governance Guidelines.

To quickly establish Sky Solar’s China operations, the Board has approved the transfer of a number of experienced senior leaders from the private entities controlled by Chairman Su to Sky Solar Holdings, Ltd. The Company expects the addition of these experts to provide the market and operating knowledge necessary for the Company to succeed in this initiative. Notable management changes include the appointment of the Company’s current Chief Investment Officer, Mr. Zhi Hao, as the new Managing Director of Sky Solar China. Mr. Yu Hu, a new addition to the Company, will be appointed as Executive Vice President of the Company and President of Sky-Link.

The Company is currently pursuing a number of financing alternatives to implement the proposed transactions associated with this strategic initiative.

About Sky Solar Holdings, Ltd.

Sky Solar Holdings is a global independent power producer (“IPP”) that develops, owns and operates solar parks and generates revenue primarily by selling electricity. Since its inception, Sky Solar has focused on the downstream solar market and has developed projects in Asia, South America, Europe, North America and Africa. The Company’s broad geographic reach and established presence across key solar markets are significant differentiators that provide global opportunities and mitigate country-specific risks. Sky Solar aims to establish operations in select geographies with highly attractive solar radiation, regulatory environments, power pricing, land availability, financial access and overall power market trends. As a result of its focus on the downstream PV segment, Sky Solar is technology agnostic and is able to customize its solar parks based on local environmental and regulatory requirements. As of September 30, 2014, the Company has developed 200 solar parks with an aggregate capacity of 181.7 MW and owns and operates 54.5 MW of solar parks.

Safe-Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends, “plans,” “believes,” “estimates” and similar statements. Among other things, the quotations from management in this press release and the Company’s operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in Sky Solar’s filings with the U.S. Securities and Exchange Commission, including its final prospectus filed pursuant to Rule 424(b)(4). Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: For Additional Information:

         Company:
         Matthew Yeh
         IR@skysolarholding.com

         Investor Relations:
         ICR, LLC
         Gary Dvorchak, CFA
         Senior Vice President
         China: +86 (10) 6583-7500
         US: +1 (310) 954-1123
         gary.dvorchak@icrinc.com

(CFD) and CTF Propose Plan to Convert to ETF Structure

Funds to seek shareholder approval for structure change that seeks a closer alignment between market price and net asset value

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced that Nuveen Commodities Asset Management (“NCAM”), the manager for the Nuveen Diversified Commodity Fund (NYSE MKT: CFD) and the Nuveen Long/Short Commodity Total Return Fund (NYSE MKT: CTF), has approved a plan to convert the Funds into open-end exchange-traded funds (“ETFs”). The purpose of the conversion plan is to seek a closer alignment between the funds’ share price and net asset value (“NAV”). The conversion of the funds to ETFs will be subject to shareholder and regulatory approvals. The funds are not currently, and after the conversion will not be, mutual funds or any other type of investment company within the meaning of the Investment Company Act of 1940.

The funds are currently structured as actively managed closed-end commodity pools. After the conversion, the funds will remain actively managed commodity pools, but they will adopt an open-end ETF structure. Under the ETF structure, investors will continue to be able to buy and sell shares of the funds on the exchange (as part of the conversion plan, the funds intend to apply to list their shares on the NYSE Arca) throughout the day at market price. In addition, the funds will adopt the creation/redemption process commonly employed by ETFs for the purpose of promoting the trading of the funds’ shares at prices equal to or near their NAV, although there can be no assurance that this process will be successful.

The conversion plan is subject to certain conditions, including shareholder and regulatory approvals. A proposal to convert the funds to ETFs will be submitted to a vote at each fund’s next annual meeting of shareholders, expected to be held on or before March 31, 2015. Prior to its annual meeting, each fund plans to file relevant materials, including a proxy statement relating to the conversion plan, with the Securities and Exchange Commission (“SEC”). Promptly after filing its definitive proxy statement, each fund will mail the proxy statement and a proxy card to each shareholder entitled to vote at the annual meeting. Shareholders are urged to thoroughly read the proxy statements (including any supplements thereto) and any other relevant documents that the funds file with the SEC when they become available, as they will contain important information. Shareholders will be able to obtain, free of charge, copies of the proxy statements and any other documents filed by the funds with the SEC in connection with the annual meetings at the SEC’s website at www.sec.gov, by calling NCAM at 877-827-5920 or by writing the funds at 333 W. Wacker Drive, Chicago, Illinois, 60606.

The conversion plan is also contingent on approval of the funds’ listing on the NYSE Arca by the exchange and the SEC, as well as other customary regulatory approvals. Assuming shareholder and regulatory approvals are obtained, NCAM anticipates that the conversion will be completed within approximately 8 to 10 months. As progress is made, updates will be provided periodically with respect to the conversion plan and time frame. There can be no assurance that such approvals will be obtained, or if obtained, that the conversions will be completed in the anticipated time frame or will achieve their stated purpose.

Gresham Investment Management, which has actively managed commodity futures investments since 1987 and which currently has over $13 billion in institutional commodity assets under management, will continue to serve as the funds’ commodity subadviser. CFD invests long in a diversified portfolio of approximately 30 exchange-traded commodity futures and options contracts in energy, agriculture, livestock, and metals. CTF invests in a long/short strategy which changes positions based on commodity price momentum, holding long, short, or flat positions in approximately 20 exchange-traded commodity futures and options contracts in energy, agriculture, livestock, and metals.

Until the conversion occurs, the funds expect to continue to pay regular monthly distributions and that the open-market share repurchase programs will remain active. As market conditions and portfolio performance may change, the funds’ distribution policies, distribution amounts, and/or frequency could change.

Investors planning to purchase shares of the funds prior to year end should refer to the tax section of their respective Information Statements, review the detailed Tax Q&A located on the Funds’ website, and consult their tax advisors. Investors who buy shares at a discount to NAV and hold them through year end may be subject to an acceleration of capital gain recognition. Important information regarding the funds’ investment strategies and risks is set forth in their respective Information Statements available on the funds’ website.

Investments in shares of the funds are subject to investment risk, including the possible loss of the entire amount invested. The funds invest primarily in commodity futures contracts and options on commodity futures contracts, which have a high degree of price variability and are subject to rapid and substantial price changes. The funds could incur significant losses on their commodity investments. The funds are not mutual funds, closed-end funds, or any other type of “investment company” within the meaning of the Investment Company Act of 1940, as amended, and are not subject to regulation thereunder. For more information about the funds, including a more complete description of risks, please see the funds’ website.

This is not a solicitation to buy or sell the funds’ shares, nor is it a solicitation of any proxy. The funds do not presently offer any new shares for sale; existing shares trade on the NYSE MKT.

Nuveen Investments provides high-quality investment services designed to help secure the long-term goals of institutional and individual investors as well as the consultants and financial advisors who serve them. Nuveen Investments markets a wide range of specialized investment solutions which provide investors access to capabilities of its high-quality boutique investment affiliates—Nuveen Asset Management, LLC, Symphony Asset Management LLC, NWQ Investment Management Company, LLC, Santa Barbara Asset Management, LLC, Tradewinds Global Investors, LLC, Winslow Capital Management, LLC and Gresham Investment Management LLC, all of which are registered investment advisers and independent investment subsidiaries of Nuveen Investments, Inc. Nuveen Commodities Asset Management, LLC (“NCAM”) NCAM is the manager of the Funds. NCAM is registered as a commodity pool operator (“CPO”) with the Commodity Futures Trading Commission (“CFTC”). Nuveen Investments operates as a separate subsidiary within TIAA-CREF, which is a leading provider of retirement and financial services in the academic, research, medical and cultural fields. In total, Nuveen Investments managed approximately $229 billion as of September 30, 2014. For more information, please visit the Nuveen Investments website at www.nuveen.com.

Forward-Looking Statements

This press release includes forward-looking statements, including statements concerning the purposes and timing of the conversion plan, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates and projections and are subject to a number of risks, uncertainties and other factors, both known and unknown, that could cause the actual results, performance, prospects or opportunities of the funds to differ materially from those expressed in, or implied by, these forward-looking statements.

You should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws or otherwise, the funds undertake no obligation to publicly update or revise any forward-looking statements or the risks, uncertainties or other factors described in this press release, as a result of new information, future events or changed circumstances or for any other reason after the date of this press release.

4953-INV-O12/15

(FLML) econd Clinical Trial With Micropump(R) Sodium Oxybate

Results Confirm Elimination of the “Middle-of-the-Night Dose” Achieved in Previous Study Meeting With FDA Will Be Requested in the First Quarter of 2015

(PARN) Management Adopts 10b5-1 Trading Plans

OVERLAND PARK, Kan., Dec. 19, 2014  — Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, reported today that Robert Joseph, President and Chief Executive Offer, and Brad McCarthy, Chief Financial Officer, have each adopted a prearranged trading plan effective December 15, 2014 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 and Parnell policy. The 10b5-1 plans call for the personal purchase of shares of company stock by Mr. Joseph and Mr. McCarthy in market transactions which commenced on December 17, 2014.

“I believe strongly in Parnell’s prospects for continued growth and success, as the company continues to advance our diversified animal health product pipeline and expand our commercial activities in the U.S. and worldwide,” said Mr. Joseph. “This is not a Parnell-sponsored stock repurchase, it is personal purchases of PARN stock by Brad and I based on our confidence in Parnell. We have adopted the 10b5-1 plans to ensure the highest level of integrity in our trading.”

Rule 10b5-1 permits officers and directors of public companies to adopt written plans for buying or selling securities in a non-discretionary, prescheduled manner when they are not in possession of material nonpublic information in order to gradually diversify their investment portfolio, to minimize the market effect of stock purchases or sales and to avoid concerns about initiating stock transactions while in possession of material nonpublic information.

About Parnell

Parnell (Nasdaq:PARN) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary software platforms – iKAM and mySYNCH. These innovative technology solutions are designed to enhance the quality of life or performance of animals, while driving customers’ operational efficiency and profitability. Parnell believes its value-added solutions help establish them as a business partner with customers rather than only as a commodity provider, differentiating them from competitors.

For more information on Parnell and its products, please visit www.parnell.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of the U.S. Private Securities Reform Act of 1995. Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “develops,” “believes,” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. Forward-looking statements represent management’s present judgment regarding future events and are subject to a number of risk and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding Parnell’s research and development activities, its ability to conduct clinical trials of product candidates and the results of such trials, as well as risks and uncertainties relating to litigation, government regulation, economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on third parties, and other factors, including those described in Parnell’s Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on September 15, 2014, along with our other reports filed with the SEC. In light of these assumptions, risks, and uncertainties, the results and events discussed in the forward-looking statements contained in this press release might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Parnell is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Parnell Pharmaceuticals Holdings
         Brad McCarthy, 913-274-2100
         brad.mccarthy@parnell.com

         BCC Partners
         Karen Bergman, 650-575-1509
         kbergman@bccpartners.com

         Susan Pietropaolo, 845-638-6290
         spietropaolo@bccpartners.com

(ADXS) Completes $17 Million Financing

PRINCETON, N.J., Dec. 19, 2014  — Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it has executed definitive securities purchase agreements with two institutional investors for gross proceeds of approximately $16.7 million in a registered direct offering of approximately 3.9 million shares at a price of $4.25 per share.

Adage Capital Management, L.P. (Adage) was the lead investor in this financing, with certain funds and accounts managed by T. Rowe Price Associates, Inc. also participating in the transaction. Proceeds from this financing will be used primarily to fund the continued clinical development of Advaxis’s cancer immunotherapy pipeline.

Adage was founded in 2001 by Robert Atchinson and Phillip Gross. Adage is a Boston based institutional money manager.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm-LLO platform technology. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead Lm-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1/2 immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis’s ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.

Advaxis’s second Lm-LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck & Co., Inc. (“Merck”), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s PD-1 checkpoint inhibitor KEYTRUDA^® (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.

Advaxis is also developing Lm-LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.

For more information please visit www.advaxis.com.

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’s ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis’s proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’s SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

KEYTRUDA is a registered trademark of Merck & Co., Inc.

(VHC) & (MSFT) Settle Pending Patent Disputes

ZEPHYR COVE, Nev. and REDMOND, Wash., Dec. 19, 2014  — VirnetX Holding Corporation (NYSE MKT: VHC) and Microsoft Corporation announced today that on December 17, 2014, VirnetX, Inc. and Microsoft Corporation have signed an Amended Settlement and License Agreement. This agreement amends and restates certain terms of the original Settlement and License Agreement, dated May 14, 2010, between VirnetX, Inc. and Microsoft Corporation. As a result of the agreement, the parties have settled their pending patent disputes.

Under the terms of the amended agreement, Microsoft has agreed to pay $23 million to VirnetX to settle the patent dispute and expand Microsoft’s license. The parties have also agreed to dismiss the patent infringement case brought by VirnetX, Inc. before the U.S. District Court for the Eastern District of Texas and jointly move to terminate the pending inter partes review proceedings between Microsoft and VirnetX, Inc. as to Microsoft.  All other aspects of the agreement were not disclosed.

“We are pleased to have come to an agreement with Microsoft Corporation and put all our legal disputes behind us,” said Kendall Larsen, Chief Executive Officer and Chairman of VirnetX, Inc.  “This agreement allows us to focus our resources towards the release of our Gabriel Secure Communication Platform™ and Gabriel Collaboration Suite™ products in the first-half of 2015 and our ongoing licensing and strategic partnership efforts.”

“Microsoft Corporation is pleased to have come to an agreement with VirnetX and that the settlement includes an expanded license to VirnetX’s entire patent portfolio,” said a Microsoft spokesperson.

About Microsoft
Founded in 1975, Microsoft (Nasdaq “MSFT”) is the worldwide leader in software, services, devices and solutions that help people and businesses realize their full potential.

About VirnetX
VirnetX Holding Corporation is an Internet security software and technology company with patented technology for secure communications including 4G LTE security.  The Company’s software and technology solutions, including its secure domain name registry and GABRIEL Connection Technology™, are designed to facilitate secure communications and to create a secure environment for real-time communication applications such as instant messaging, VoIP, smartphones, eReaders and video conferencing.  The Company’s patent portfolio includes over 107 U.S. and international patents with over 100 pending applications.  For more information, please visit www.virnetx.com.

Forward Looking Statements
Statements in this press release that are not statements of historical or current fact, including statements regarding the  strength of Virnetx’s intellectual property, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are based on expectations, estimates and projections about the markets in which the Company operates, management’s beliefs, and certain assumptions made by management and involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements, including but not limited to (1) the outcome of any legal proceedings that have been or may be initiated by the Company or that may be initiated against the Company;, including pending and future inter partes review proceedings in the Patent and Trademark Office (2) the ability to capitalize on the Company’s patent portfolio and generate licensing fees and revenues; (3) the ability of the Company to be successful in entering into licensing relationships with its targeted customers on commercially acceptable terms; (4) potential challenges to the validity of the Company’s patents underlying its licensing opportunities; (5) the ability of the Company to achieve widespread customer adoption of the Company’s GABRIEL Communication Technology™ and its secure domain name registry; (6) the level of adoption of the 3GPP Series 33 security specifications; (7) whether or not the Company’s patents or patent applications may be determined to be or become essential to any standards or specifications in the 3GPP LTE, SAE project or otherwise; (8) the extent to which specifications relating to any of the Company’s patents or patent applications may be adopted as a final standard, if at all; and (9) the possibility that Company may be adversely affected by other economic, business, and/or competitive factors.  In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” or “plans” to be uncertain and forward-looking.  The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading “Risk Factors” in Company’s Quarterly Report on Form 10-Q filed with the SEC on November 10, 2014.  Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s  ability to control or predict.  Except as required by law, the Company is under no duty to update any of the forward-looking statements after the date of this press release to conform to actual results.

Contact:
Greg Wood
VirnetX Holding Corporation
775.548.1785
greg_wood@virnetx.com

David Cuddy
Microsoft Corporation
425.421.2502
dcuddy@microsoft.com

VirnetX and GABRIEL Connection Technology are trademarks of VirnetX Holding Corporation. Other company and product names may be trademarks of their respective owners

(TRXC) Pre-Clinical Robotic Surgical Procedures Complete; FDA Timeline Affirmed

SurgiBot system FDA 510(k) filing on track for mid-2015 submission

TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the successful completion of four general surgery and urology procedures using its SurgiBot system patient-side robotic surgery system. Management also stated that the preparation of its FDA 510(k) filing is proceeding as planned, and affirmed prior guidance of its intention to submit the filing in mid-2015.

Using the SurgiBot system in the porcine model, Dr. Juan-Carlos Verdeja, a general surgeon and Chief of General Surgery at Baptist Health Medical Group in Miami, performed two cholecystectomy (gallbladder removal) procedures, and Dr. Michael N. Ferrandino, a urologist and Director of Minimally Invasive Urologic Surgery at the Duke Division of Urology, performed two nephrectomy (kidney removal) procedures.

“The SurgiBot system has the ability to offer multiple instruments and a camera through a single small incision. It is designed to limit surgical trauma while enabling the surgeon with advanced vision, dexterity and control,” said Dr. Verdeja. “I was impressed with the system’s capabilities, providing ergonomic benefits as well as excellent visualization in 3DHD. Being able to perform the procedure from within the sterile field, and with tactile feedback, increases the control a surgeon has when performing surgery.”

Dr. Ferrandino commented, “I can envision the SurgiBot being utilized in a wide variety of surgical procedures. This system provides an elegant and effective combination of the best of single-port, laparoscopic and robotic approaches in surgery.”

“These pre-clinical procedures support our expectation for commercial success with the SurgiBot,” said Todd M. Pope, president and CEO of TransEnterix. “We are pleased with our progress and our FDA 510(k) filing remains on track for a mid-2015 submission.”

About SurgiBot

The SurgiBot system, currently in development, is a minimally invasive, patient-side robotic surgery system. The system utilizes flexible instruments through articulating channels controlled directly by the surgeon, with robotic assistance, at the patient’s bedside. The flexible nature of the system allows for multiple instruments to be introduced and deployed through a single incision. The SurgiBot system has not been cleared by the FDA for use the in United States.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery. The company is focused on the development and commercialization of the SurgiBot system, a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field. For more information, visit the company’s website at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to the SurgiBot system, our flexible energy device and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations, including whether we will successfully submit our SurgiBot system regulatory filings in mid-2015, whether we will be able to successfully commercialize the SurgiBot system and whether the SurgiBot system will be able to be utilized in a wide variety of procedures. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the SurgiBot system’s 510(k) application(s) will be cleared by the U.S. FDA. For a discussion of the most significant risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2013 filed on March 5, 2014 as amended, and other filings we make with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

(UBIC) Development of an AI-Based IP Property Valuation Tool w/ Toyota

TOKYO, Dec. 18, 2014  — UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) (“UBIC” or “the Company”), a leading provider of international litigation support and big-data analysis services, has commenced development of an AI-based intellectual property valuation tool in a joint project with Toyota Technical Development Corporation (“TTDC”).

In recent years, patent surveys in the manufacturing industry have seen a wider range of technology information subject to surveys, resulting in the necessity to study larger amounts of data. This is particularly true for electronic control technologies in the automotive industry, the research and development field of which has recently witnessed remarkable expansion. In addition, competition has been fierce in the automotive technology field relating to safety performance and fuel efficiency among other things, as well as in research and development for next-generation mobility. Accordingly, patent surveys for establishing rights to new technologies end up being labor-intensive processes.

In response to these trends, UBIC is partnering with TTDC in a joint effort to develop the Intellectual Property Virtual Data Scientist (VDS), an AI-based tool for intellectual property valuation. The Virtual Data Scientist, which is under development by UBIC, utilizes artificial intelligence capable of analyzing big data and learning from specialists’ decisions. Above all, the tool is able to learn outstanding tacit knowledge for analyses. It also learns from the discerning judgments made by specialists in a specific business domain and from the know-how accumulated in the domain through actual surveys. Therefore, UBIC expects that Intellectual Property VDS will significantly improve the efficiency of patent valuation operations of a company which employs intellectual property specialists (such as people from R&D and intellectual property departments and patent attorneys) by reducing the time spent on the evaluation operations.

Through the development of Intellectual Property VDS, UBIC will help create an environment which allows people working in intellectual property-related functions to concentrate on higher-level survey operations, thereby contributing to the development of the intellectual property field.

About TTDC

Since Toyota Technical Development Corporation (TTDC)’s establishment in 2006 as Toyota Motor Corporation (TMC)’s technological development partner, TTDC has played a key role in vehicle development.

On November 26, 2014, TMC and TTDC have agreed to reorganize TTDC on January 1, 2016.

The reorganization will enable TTDC to focus solely on development support such as intellectual property and effectively utilize its accumulated practical expertise. TTDC will be able to expand its services to support other members of the Toyota Group, thus helping to strengthen the vehicle development capabilities across the entire group.

For more information please visit: URL: http://www.toyota-td.jp/.

About UBIC

UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) is a leading provider of e-discovery and digital forensic services for Asia and the world. UBIC has extensive experience working with electronically stored information composed in Chinese, Japanese and Korean (CJK) languages and utilizes that expertise for clients involved in cross-border litigation, corporate investigations, intellectual property disputes and much more. At the forefront of e-discovery innovation, UBIC’s proprietary Lit i View® platform is moving the industry from “fact discovery” to “future discovery” by allowing clients to analyze e-mail messages and digital communications found in big-data to reveal patterns in human thought and behavior.

For more information about UBIC, contact usinfo@ubicna.com

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the amount of data that UBIC expects to manage this year and the potential uses for UBIC’s new service in intellectual property-related litigation, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC’s goals and strategies; UBIC’s expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC’s services; UBIC’s expectations regarding keeping and strengthening its relationships with customers; UBIC’s plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC’s reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.

CONTACT: Yukari Nakajima
         UBIC North America, Inc.
         Tel: (212) 924-8242
         yukari_nakajima@ubic.co.jp

(TLOG) Initiation Of Phase 2 Clinical Trial of SHAPE in Cutaneous T-Cell Lymphoma

MALVERN, Pa., Dec. 18, 2014  — TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T‑cell lymphoma (“CTCL”).

SHAPE has been evaluated in a randomized, dose escalation, placebo-controlled Phase 1 clinical trial in early-stage CTCL subjects that met safety endpoints and demonstrated clinical activity. Four of fifteen patients receiving SHAPE attained an objective response as measured by a greater than 50% improvement in their Composite Assessment of Index Lesion Severity, or CAILS, score during and after 28 days of dosing. No placebo patients responded.

The randomized Phase 2 trial will be conducted in approximately sixty subjects with Stage IA-IIA CTCL. The objectives of the Phase 2 clinical trial are to evaluate the dose, clinical effect at 6 months (based on CAILS score), time to response, and tolerability of treatment of >2% body surface area.

“We are excited to advance our second molecule into a randomized Phase 2 trial,” said J. Kevin Buchi, President and Chief Executive Officer of TetraLogic. “SHAPE’s Phase 1 data suggests that it may provide significant clinical benefit over existing CTCL therapies, and we are hopeful that those data are replicated over a longer duration and a broader body surface area.”

About SHAPE

SHAPE is an HDAC inhibitor being developed for topical use for the treatment of cutaneous T‑cell lymphoma, or CTCL. SHAPE is a novel therapeutic designed to maximize HDAC inhibition locally in the skin with limited systemic exposure. As a result, SHAPE has characteristics that could allow it to be used topically over large body surface areas with minimal systemic absorption. SHAPE’s composition of matter patent in the U.S. extends until at least 2028; in addition, SHAPE has been granted U.S. orphan drug designation for CTCL. We have acquired worldwide development and commercialization rights to SHAPE for all indications.

About TetraLogic Pharmaceuticals Corporation

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors, and is also being tested in a Phase 1b/2a clinical trial in hepatitis B. SHAPE is currently being tested in a Phase 2 clinical trial for early-stage cutaneous T‑cell lymphoma.

Forward Looking Statements

Some of the statements in this release are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or TetraLogic’s pre-clinical and clinical development of birinapant, SHAPE and other clinical programs, future expectations, plans and prospects. Although TetraLogic believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. TetraLogic has attempted to identify forward looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 19, 2014 and in our form 10-Q filed with the SEC on November 5, 2014. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT: Company Contact:
         Pete A. Meyers
         Chief Financial Officer and Treasurer
         TetraLogic Pharmaceuticals Corporation
         (610) 889 - 9900, x103
         Pete.meyers@tlog.com

         Investor Relations Contact:
         Ami Bavishi
         Burns McClellan, Inc.
         (212) 213-0006
         abavishi@burnsmc.com

(STEM) Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury

Pathway Study to Assess the Potential of Human Neural Stem Cells to Restore Motor Function

NEWARK, Calif., Dec. 18, 2014  — StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II Pathway^® Study assessing the efficacy of its proprietary HuCNS-SC^® (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI). The transplant was performed at the University of Miami Hospital within the Miller School of Medicine, home to The Miami Project to Cure Paralysis, one of the world’s most comprehensive spinal cord injury research centers dedicated to finding effective treatments for paralysis.

“The participant tolerated the procedure well and is recovering from the surgery as expected,” said Allan D. Levi, M.D., Ph.D., F.A.C.S., Robert M. Buck Distinguished Chair in Neurological Surgery at the University of Miami Miller School of Medicine and Principal Investigator for the center. “Our center is a leader in clinical research aimed at curing paralysis, and we are excited to be participating in this breakthrough approach to spinal cord injury repair. The Pathway study is designed to measure the potential of these human neural stem cells, HuCNS-SC, as a possible treatment for repairing some aspects of spinal cord injury. Restoring or improving motor function would be life changing for these patients.”

The Pathway Study is the first clinical trial designed to evaluate both the safety and efficacy of transplanting human neural stem cells into patients with cervical spinal cord injury. Traumatic injuries to the cervical (neck) region of the spinal cord, also known as tetraplegia or quadriplegia, impair sensation and motor function of the hands, arms, legs, and trunk. The trial will be conducted as a randomized, controlled, single-blind study and efficacy will be primarily measured by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms, and shoulders. The trial will follow the participants for one year and will enroll up to 52 subjects.

“We are working with all due speed to pioneer a revolutionary therapeutic approach for victims of spinal cord injury, a debilitating condition that has significant unmet need and no effective treatment,” said Stephen Huhn, M.D., FACS, FAAP, Vice President, Clinical Research and CMO at StemCells, Inc. “Enrollment of the first patient with cervical injury is an important step in our clinical development, which ultimately has the goal of improving motor function and restoring a level of independence for individuals living with chronic spinal cord injury. The Pathway Study is a natural evolution from our Phase I/II trial in thoracic spinal cord injury.”

The Company completed enrollment and dosing in its open-label Phase I/II study in thoracic spinal cord injury in May 2014 and has reported interim results on all 12 subjects. Post-transplant gains in sensory function below the level of injury were demonstrated in half of the subjects. Two subjects converted from a complete injury (AIS A) to an incomplete injury (AIS B). The interim results also continue to confirm the favorable safety profile of the cells and the surgical procedure.

About the Pathway Spinal Cord Injury Clinical Trial

The StemCells, Inc. Pathway Phase II clinical trial, titled “Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury,” will evaluate the safety and efficacy of transplanting the Company’s proprietary human neural stem cells (HuCNS-SC cells), into patients with traumatic injury in the cervical region of the spinal cord. Conducted as a randomized, controlled, single-blind study, the trial will measure efficacy by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms and shoulders. The trial will enroll approximately 52 subjects and follow the patients for 12 months post-transplant.

Information about the Company’s spinal cord injury program can be found on the StemCells, Inc. website at:

http://www.stemcellsinc.com

Patient testimonials from the Phase I/II study can be found at:

http://www.stemcellsinc.com/News-Events/Video-Library.htm

Information for patients interested in participating in the study is available at the Pathway website at:

http://www.sciresearchstudy.com

Additional information about the clinical trial is available at:

http://clinicaltrials.gov/ct2/show/NCT02163876?term=stem+cells+cervical+spinal+cord+injury&rank=1

About HuCNS-SC Cells

StemCells, Inc. has demonstrated human safety data from completed and ongoing clinical studies in which its proprietary HuCNS-SC cells have been transplanted directly into all three components of the central nervous system: the brain, the spinal cord and the eye. StemCells, Inc. clinicians and scientists believe that HuCNS-SC cells may have broad therapeutic application for many diseases and disorders of the CNS. Because the transplanted HuCNS-SC cells have been shown to engraft and survive long-term, there is the possibility of a durable clinical effect following a single transplantation. The HuCNS-SC platform technology is a highly purified composition of human neural stem cells (tissue-derived or “adult” stem cells). Manufactured under cGMP standards, the Company’s HuCNS-SC cells are purified, expanded in culture, cryopreserved and then stored as banks of cells, ready to be made into individual patient doses when needed.

About StemCells, Inc.

StemCells, Inc. is currently engaged in clinical development of its HuCNS-SC (purified human neural stem cells) platform technology, as a potential treatment for diseases and disorders of the central nervous system. Interim data from the Company’s Phase I/II clinical trial in thoracic spinal cord injury shows measurable gains involving multiple sensory modalities and segments in half of the subjects, two of whom converted from complete injury (AIS A) to incomplete injury (AIS B), post-transplant. Enrollment has recently commenced in the Company’s Phase II clinical trial in cervical SCI. StemCells, Inc. has also completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration (GA-AMD), the most severe form of dry AMD, which is the leading cause of blindness in the elderly. Interim results for those subjects with 12 month follow-up post transplantation of HuCNS-SC cells into the eye, show a reduction in the rate of disease progression as compared to the control (untreated) eye and to the expected natural history of the disease. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. Further information about StemCells, Inc. is available at http://www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding whether the improvements in sensory function seen in the Company’s Phase I/II clinical study of spinal cord injury will persist and whether they will prove to be clinically meaningful; the prospect for evaluating trial patients for changes in their sensation, motor function and bowel/bladder function; the potential of the Company’s HuCNS-SC cells to treat spinal cord injury and other central nervous system disorders; and the future business operations of the Company, including its ability to conduct clinical trials as well as its other research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company’s HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the FDA or other applicable regulatory agencies will permit the Company to continue clinical testing in spinal cord injury or in future clinical trials of proposed therapies for other diseases or conditions; uncertainties regarding the Company’s ability to recruit the patients required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding the Company’s ability to manufacture viable cells sufficient to enroll the patients planned for the Company’s Phase II studies; uncertainties regarding the Company’s ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company’s cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; and other factors that are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, and in its subsequent reports on Form 10-Q and Form 8-K.

CONTACT: Greg Schiffman
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128

         Andrea Flynn
         Russo Partners
         (646) 942-5631

(AGEN) Positive Phase 3 Study, (GSK) Shingles Vaccine w/ Agenus Adjuvant

• GSK’s ZOE-50 Phase 3 study meets primary endpoint of reducing the risk of shingles in people aged 50 and older
• Agenus is entitled to receive royalties on potential commercial sales of HZ/su

LEXINGTON, Mass., Dec. 18, 2014 — Agenus Inc. (Nasdaq:AGEN), an immuno-oncology company developing a broad portfolio of checkpoint modulators (CPMs) and heat shock protein peptide-based vaccines as well as adjuvants, announced that its partner GlaxoSmithKline (NYSE:GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 per cent in adults aged 50 years and older compared to placebo.

HZ/su is a novel candidate vaccine that combines gE, a protein found on the varicella-zoster virus that causes shingles, with GSK’s Adjuvant System, AS01_B, which serves to stimulate a stronger immunological response to the vaccine. Agenus’ QS-21 Stimulon® adjuvant is one of the key components of AS01, which is used in other vaccine candidates undergoing clinical development.

Agenus is entitled to receive royalties on potential commercial sales of HZ/su.

“We are thrilled with the results of this important study,” said Garo Armen, Ph.D., Chief Executive Officer of Agenus, “The results indicate unprecedented protection against shingles. HZ/su is the second candidate vaccine containing QS-21 saponin to produce positive phase 3 results.”

The study, which started in August 2010, is a randomized, placebo-controlled, multicenter, international study involving 16,136 adults aged 50 and older. An additional GSK trial to evaluate the ability of HZ/su to prevent shingles is underway in adults aged 70 and older (ZOE-70). This study will provide additional information on the efficacy of HZ/su vaccine candidate in preventing some of the complications of shingles, the most common being chronic neuropathic pain, also known as post-herpetic neuralgia (PHN)ⁱ.

Data from GSK’s ZOE-50 study are expected to be presented at a forthcoming scientific conference and will be submitted for publication in a peer-reviewed journal.

About shingles

Shingles typically presents as a painful, itchy rash that develops on one side of the body, as a result of reactivation of latent chickenpox virus (varicella-zoster virus, VZV). Complications from shingles can include scarring, vision complications, secondary infection, nerve palsies and PHN, the most common complication. The lifetime risk of developing shingles is approximately 1 in 3.

About QS-21 Stimulon

Agenus’ flagship adjuvant, QS-21 Stimulon^® adjuvant, is a saponin extracted from the bark of the Quillaja saponaria tree, also known as the soap bark tree, an evergreen tree native to warm temperate central Chile. Agenus’ QS-21 Stimulon has become a key component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases and in several investigational therapeutic vaccines intended to treat cancer and degenerative disorders. QS-21 Stimulon has been widely studied in approximately 50,000 people. Agenus is generally entitled to receive milestone payments as QS-21 Stimulon containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.

About Agenus

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte Display® is used to generate fully human and humanized therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus’ heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. The company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen and includes several vaccine candidates in Phase 2 and Phase 3 clinical trials. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding research and development and clinical trial activities and results, the presentation and publication of data, potential revenue streams, and the potential application of the Company’s and its licensee’s technologies and product candidates in the prevention and treatment of diseases. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recently filed Quarterly Report on Form 10-Q with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus’ business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus’ business and securities, investors should give careful consideration to these risks and uncertainties.

Agenus includes its affiliates for purposes of this press release. Retrocyte Display and Stimulon are registered trademarks of Agenus Inc. and its subsidiaries.

ⁱ Johnson, RW et al N Engl J Med 2014;371:1526-33

CONTACT: Brad Miles
         BMC Communications
         646-513-3125
         bmiles@bmccommunications.com

(OBCI) CEO Explains Its New Disinfectant, Effective and Safe against Viruses, Germs, Bacteria

Launching Product in Numerous Huge Markets

FORT LAUDERDALE, Fla., Dec. 18, 2014 — Ocean Bio-Chem, Inc. (NASDAQ: OBCI) said today in an interview with CEOLIVE.TV that its new product, Performacide^®, kills bacteria, mold, mildew and non-enveloped viruses that the CDC has issued guidance on including a disinfectant for Ebola.

Performacide^® has been approved and registered with the United States Environmental Protection Agency, as well as all 50 state environmental agencies. The CEO interview can be viewed in its entirety at: https://www.youtube.com/watch?v=qeSLD2juFzk. Ocean Bio-Chem owns 100 percent of the patents for the chlorine dioxide generating system which allows retail as well as commercial applications to safely and efficiently use Performacide^®. The product has already been sent to Africa to aid in the fight against the Ebola virus.

Ocean Bio-Chem. Inc. President and CEO Peter Dornau in the interview said the Company has added a Vice President of Sales & Marketing to market and sell this product to potential large markets, including hospitals, cruise ship lines, veterinary offices, food processing and the household retail sector.

Jeff Barocas, CFO, said, “There will be no patent royalty payments and no partners. One hundred percent of the profit from the sale of the products will accrue to Ocean Bio-Chem after buying out our partners earlier in the year.”

Mr. Dornau also explained that Performacide® can safely kill the microorganisms that prematurely destroy food and that the Company is studying applications in that sector also.

Ocean Bio-Chem, Inc. is principally engaged in the manufacturing, marketing and distribution of a broad line of appearance and maintenance products for boats, recreational vehicles, automobiles, power sports, outdoor power equipment and motorcycle markets under the Star brite^® StarTron^® and other trademarks within the United States of America and Canada. In addition, the Company produces private label formulations of many of its products for various customers and provides custom blending and packaging services for these and other products. It manufactures its products in a 300,000 square foot facility in Montgomery, Alabama, from which they are distributed across the globe.

The Company trades publicly under NASDAQ Capital Markets, Ticker Symbol: OBCI.

The Company’s web sites are:
www.oceanbiochem.com, www.Starbrite.com, www.Startron.com, www.nos-guard.com, and www.performacide.com

About CEOLIVE.TV:

CEOLIVE is an investor media provider featuring publicly traded companies. Presentations address topics related to the company’s business performance and strategy but are not intended to provide the first announcement of material information or developments. They will discuss matters announced through other channels or that are not themselves considered material information under securities laws, even though the matters may be important to shareholders. To find out more, please visit: http://www.ceolive.tv.

Forward-looking Statements:
Certain statements contained in this Press Release including without limitation expectations as to future sales and operating results, constitute forward-looking statements. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “believe,” “may,” “will,” “expect,” “anticipate,” “intend,” “could” including the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that may affect these results include, but are not limited to, the highly competitive nature of our industry, reliance on certain key customers, changes in consumer demand for marine, recreational vehicle and automotive products, advertising and promotional efforts, exposure to market risks for changes in interest rates and in foreign exchange rates, and other factors.

Contacts:

Peter Dornau
President & CEO
pdornau@starbrite.com
954-587-6280

Jeff Barocas
Vice President & CFO
Jbarocas@starbrite.com
954-587-6280

Paul Knopick
E & E Communications
pknopick@eandecommunications.com
940-262-3584

(RBY) Begins Stockpiling Mill Feed for Projected Production Commencing Mid-2015

Rubicon Minerals Corporation
Allan Candelario
Director of Investor Relations
+1 (866) 365-4706
ir@rubiconminerals.com
www.rubiconminerals.com

(DLNG) Announces Transfer of Listing of Common Units to NYSE

(INS) to Explore Strategic Initiatives

NORCROSS, Ga., Dec. 17, 2014  — Intelligent Systems Corporation (NYSE MKT:INS) today confirmed that it intends to more actively explore strategic alternatives to enhance shareholder value. Management has historically articulated a strategy to both invest in new technologies or companies (and has supported an incubator program since the late ’90s) and to sell off assets or subsidiaries, either in whole or in part, when the Board and Management determine it is in our shareholders’ best interests. The company regularly considers a broad range of strategic alternatives with the goal of enhancing shareholder value.

Today, the company’s two major operating businesses are ChemFree Corporation and CoreCard Software, as well as minority investments in several other companies. Recently, the company has been approached with indications of interest for both of our major subsidiaries.  No due diligence has transpired nor have any agreements been reached. However, we believe there is sufficient interest that more comprehensive discussions are likely which may result in formal due diligence with respect to one or both businesses.

Because of the relative sizes of the two businesses, a transaction involving either one would have a substantial impact on the company in many ways. If a cash transaction occurred, the company would expect to have cash in excess of what is required for operating the remaining subsidiary. Therefore we would have to consider whether to invest in something new or return cash to our shareholders. If both businesses were sold in the near term (a prospect we do not consider likely but it cannot be dismissed), a decision would then be made as to whether to continue operations or to liquidate the company and provide the proceeds from the sale(s) to the shareholders.

One of the reasons for issuing this release at this time (in addition to recent indications of interest) is that TheStreet Ratings last week listed INS as a sell recommendation and we believe investors may not be aware of the regular and on-going management efforts to increase shareholder value.  Leland Strange, President and CEO, who is a significant holder of INS stock, stated, “I believe the intrinsic value of the company is higher than the current trading range of our shares would indicate, while recognizing that nothing is certain until a transaction proves otherwise.  We are constantly looking at ways to capitalize on our investments and will continue to do so.”

The company does not have a definitive timetable for exploring these strategic alternatives and it does not intend to provide updates or comment further regarding this process unless a specific transaction is approved by the Board of Directors or the review process is concluded.  It is possible that this consideration of strategic alternatives will lead to the conclusion that the company’s shareholders are best served by continuing to own and operate our current businesses for the present time.

For further information about our business, operating companies and industry sectors, investors may read the company’s Form 10-Q and Form 10-K filings at www.sec.gov or www.intelsys.com.

About Intelligent Systems Corporation

For over thirty five years, Intelligent Systems Corporation (NYSE MKT:INS) has identified, created, operated and grown early stage technology companies. The company has operations and investments in the information technology and industrial products industries. The company’s principal majority-owned subsidiaries are CoreCard Software, Inc. (www.corecard.com), a provider of software and services for prepaid and credit card processing, and ChemFree Corporation (www.chemfree.com), a leader in bioremediating parts washer equipment and supplies.  Further information is available on our website at www.intelsys.com or by calling us at 770-381-2900.

In addition to historical information, this news release may contain forward-looking statements relating to Intelligent Systems Corporation and its subsidiary and affiliated companies. These statements include all statements that are not statements of historical fact regarding the intent, belief or expectations of Intelligent Systems Corporation and its management with respect to, among other things, results of operations, product plans, and financial condition. The words “may,” “will,” “anticipate,” “believe,” “intend,” “expect,” “estimate,” “plan,” “strategy” and similar expressions are intended to identify forward-looking statements. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. The company does not undertake to update or revise any forward-looking statements whether as a result of new developments or otherwise, except as required by law. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are instability in the financial markets, delays in product development, undetected software errors, competitive pressures, changes in customers’ requirements or financial condition, market acceptance of products and services, changes in the performance, financial condition or valuation of affiliate companies, the risks associated with investments in privately-held early stage companies and further declines in general economic and financial market conditions, particularly those that cause businesses to delay or cancel purchase decisions.

CONTACT: Bonnie Herron
         770-564-5504
         bherron@intelsys.com

(OVAS) Advances All Three Fertility Treatment Options

OvaScience^SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today announced the Company has achieved its 2014 corporate goals to advance the AUGMENT^SM, OvaPrime^SM and OvaTure^SM treatments for patients in need of new fertility treatment options.

“We are pleased to report that we have successfully matured human egg precursor cells into eggs in vitro. This is a major milestone for the first potential hormone-free fertility option, the OvaTure treatment. We have achieved this by designing an autologous, high throughput in vitro system, which we believe will accelerate further development of the OvaTure treatment, the only hormone-free fertility option,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience.

AUGMENT Treatment
The AUGMENT fertility treatment is available in select in vitro fertilization (IVF) clinics in Canada, the United Kingdom (UK), the United Arab Emirates (UAE) and Turkey. The AUGMENT treatment is not available in the United States. OvaScience has a further commitment from one of the largest IVF clinic networks in Japan, which plans to offer the treatment in 2015. For further information, please visit the new AUGMENT treatment website at www.augmenttreatment.com.

The AUGMENT treatment is specifically designed to improve egg health by using mitochondria from a patient’s own egg precursor (EggPC^SM) cells during IVF. Improved egg health may offer the potential for better IVF success. OvaScience exceeded its AUGMENT patient treatment goal with more than 150 patients now receiving the treatment. The Company has started transitioning some of the IVF clinics to commercial centers.

OvaPrime Treatment
The OvaPrime treatment is a potential new fertility treatment that uses EggPC cells to increase a woman’s egg reserve. The OvaPrime treatment may provide an option for women who do not produce enough or any high-quality eggs. OvaScience plans to optimize the process and introduce the OvaPrime treatment in certain IVF clinics in select international regions outside of the United States by the end of 2015.

As anticipated, OvaScience has performed additional preclinical proof-of-concept work for the OvaPrime treatment that supports previously published research, which demonstrated that EggPC cells can mature into eggs in the ovary (in vivo).

OvaTure Treatment
The OvaTure treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without the need for hormone injections. The Company is the first to demonstrate that human EggPC cells can be matured into eggs outside of the body, and therefore has achieved human preclinical proof-of-concept with the OvaTure treatment. This is a major step toward being able to offer women with compromised eggs, who are unable to make eggs, or who may be unwilling or unable to undergo hormone hyperstimulation, a new treatment option.

“Our ability to demonstrate additional proof-of-concept for the OvaPrime and OvaTure treatments underscores the potential of our EggPC technology for developing new fertility treatments,” said Arthur Tzianabos, Ph.D., President of OvaScience. “We look forward to being able to provide women with more treatment options that may improve egg health and, importantly, would not require hormones.”

OvaScience Investor Day
The Company is hosting an Investor Day today, Wednesday, December 17, 2014 in New York beginning at 8:00 a.m. The event will feature presentations by guest speakers and Company management on the EggPC cell technology and the global fertility market as well as an update on OvaScience’s fertility treatments. A live audio webcast can be accessed by visiting the Investors section of the Company’s website at www.ovascience.com. A replay of the webcast will be archived on the OvaScience website for two weeks following the presentation.

About OvaScience
OvaScience (NASDAQ: OVAS) is a global life sciences company dedicated to improving fertility for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC^SM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT^SM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrime^SM treatment, which could increase a woman’s egg reserve, and the OvaTure^SM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.

Forward-Looking Statements
This press release includes forward-looking statements about the Company’s (i) plans for a launch of the AUGMENT treatment in Japan in 2015, (ii) plans to optimize the OvaPrime treatment and introduce it in select IVF clinics outside the United States by the end of 2015, (iii) plans to provide women with more treatment options that may improve egg health and not require hormones, and (iv) plans and treatment possibilities for the AUGMENT treatment and its two fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with, including the IVF clinic in Japan that plans to offer the AUGMENT treatment in 2015, may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval as necessary for our internationally launched fertility treatment and our potential fertility treatments; our ability to develop our potential fertility treatments, including the AUGMENT treatment, OvaPrime treatment and OvaTure treatment, on the timelines we expect, if at all; our ability to commercialize our treatments, including the AUGMENT treatment and OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

Investors
OvaScience
Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer
tmcneely@ovascience.com
or
Media
OvaScience
Cara Petralia, 617-714-9638
Director, Corporate Communications
cpetralia@ovascience.com
or
FleishmanHillard
Catherine Collier Kyroulis, 917-886-5586

(MBII) REGALIA(R) MAXX Biofungicide Receives Registration in Brazil

First Approved Plant Extract-Based Fungicide in Brazil Brings Growers New Solution for Protecting Against Disease, Resulting in Higher Quality and Yields

DAVIS, Calif., Dec. 17, 2014  — Marrone Bio Innovations, Inc. (MBI), (Nasdaq:MBII), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, today announced that its REGALIA^® MAXX Biofungicide has received a product registration from Brazil’s Ministry of Agriculture (MAPA). Brazil now joins Peru, El Salvador, Guatemala, Honduras, Panama, Columbia, the Dominican Republic and Mexico as Latin American countries having approved the use of REGALIA MAXX to control a wide variety of bacterial and fungal diseases across an array of agricultural crops.

REGALIA MAXX is the first plant extract-based fungicide approved in Brazil and is the first biopesticide with Induced Systemic Resistance (ISR), a complex mode of action which creates a defense response in the treated plants and stimulates additional biochemical pathways that strengthen the plant structure and act against the pathogen. The newly approved uses for REGALIA MAXX in Brazil, include tomatoes, potatoes, and dried beans. MBI is working with its partner FMC to expand the label to include a broader array of crops and diseases, such as citrus and row crops.

“REGALIA MAXX brings Brazilian growers an environmentally responsible and effective solution for protecting against a variety of fungal and bacterial diseases, resulting in higher quality and improved yields,” said MBI, CEO Pam Marrone. “This registration is critical to our global expansion plan for MBI products and we believe it will fill a real need for growers in Brazil. REGALIA MAXX can be used as a standalone product or in combination with other fungicides to strengthen integrated pest management programs, improve plant health and boost yields.”

REGALIA MAXX is an advanced biofungicide that can minimize chemical residues by being used alone in a disease-control program, particularly for exported crops at the end of the season right before harvest or in rotation with synthetic fungicides or in a tank mix. The product induces a plant’s natural defenses to protect against a variety of fungal and bacterial diseases and features multiple modes of action, which helps to prevent or delay the development of disease resistance. It also provides a four-hour re-entry interval that increases operational flexibility and a zero-day post-harvest interval so crop quality can be protected right up to harvest. REGALIA MAXX is proven to control diseases such as powdery mildews on cucurbits (melons, cucumber, zucchini), cane berries, tomatoes (including tomatillo), eggplant, peppers, grapes and ornamentals; Alternaria on tomatoes and potatoes; anthracnose on avocado, mango, papaya and citrus.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc. (Nasdaq:MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.

Forward Looking Statements

Portions of this press release may constitute “forward-looking statements,” and assumptions underlying such forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any such forward-looking statements are made within the “safe-harbor” protections of the PSLRA, should not be relied upon as representing our views as of any subsequent date, and we are under no obligation to, and expressly disclaims any responsibility to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements in this filing include those regarding: the anticipated filing date of the Company’s Form 10-Q and the Company’s expectations regarding regaining full compliance with NASDAQ continued listing requirements. Such forward-looking statements are based on information available to us as of the date of this release and involve a number of risks and uncertainties, some beyond our control, that could cause actual results to differ materially from those anticipated by these forward-looking statements. Such risks include the uncertainty surrounding the timing and results of the Audit Committee’s independent investigation of accounting matters, the potential need for restatement of our prior period financial statements, how promptly the investigation of accounting matters can be completed and any results thereof can be resolved, and potential legal or regulatory action related to the matters under investigation. In addition, the Company faces other risks and uncertainties that could affect its ability to complete the filing of its Form 10-Q and to regain compliance with the NASDAQ listing requirements. Additional information that could lead to material changes in our performance is contained in our filings with the Securities and Exchange Commission.

CONTACT: Media Contact:

         Cory Ziskind
         ICR
         646-277-1232
         Cory.Ziskind@icrinc.com

(TTPH) Positive Top-line Results, Phase 3 IGNITE 1 Clinical Trial of Eravacycline

Eravacycline achieves primary endpoint in first of two pivotal trials– —Company to host conference call at 4:30 p.m. ET today

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive top-line results from IGNITE 1, the Company’s Phase 3 clinical trial of eravacycline for the treatment of complicated intra-abdominal infection (cIAI) compared to ertapenem. In the trial, eravacycline met the primary endpoint of statistical non-inferiority of clinical response at the test-of-cure (TOC) visit, under the guidance set by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The primary analysis under the FDA guidance was conducted using a 10% non-inferiority margin in the microbiological intent-to-treat (micro-ITT) population. In the micro-ITT population, the lower and upper bounds of the 95% confidence interval were -7.1% and 5.5%, respectively. Under the EMA guidance, the primary analysis was conducted using a 12.5% non-inferiority margin of the clinically evaluable (CE) patient population. In the CE population, the lower and upper bounds of the 95% confidence interval were -6.3% and 2.8%, respectively. The secondary analyses were consistent with and supportive of the primary outcome.

There were no drug-related serious adverse events in the trial. The most commonly reported drug-related adverse events for eravacycline were gastrointestinal, including nausea (3.3%) and emesis (2.2%). This adverse event profile for eravacycline was consistent with that seen in the Phase 2 clinical trial of eravacycline in cIAI.

The spectrum of pathogens in this trial was similar to that seen in other pivotal trials in this patient population. The most common Gram-negative pathogens in the study included Escherichia coli, Klebsiella pneumonia, Pseudomonas and Bacteroides.

“The prevalence of potentially deadly, multi-drug-resistant bacterial infections has grown rapidly in recent years and is currently a major global public health concern, especially in resistant Gram-negative infections where many current antibiotic treatment options are increasingly ineffective,” commented Joseph Solomkin, M.D., Professor Emeritus in the Department of Surgery at the University of Cincinnati College of Medicine and advisor to the Company. “These IGNITE 1 trial results suggest that eravacycline has the potential to be a new treatment option for serious intra-abdominal infections, and possibly other serious bacterial infections, where new treatments are urgently needed for patients.”

“The positive results from IGNITE 1 underscore that treatment with eravacycline could help a significant number of cIAI patients achieve a clinical cure for their difficult-to-treat Gram-negative infections,” said Guy Macdonald, President and CEO of Tetraphase. “The success of this trial is an important milestone for the eravacycline pivotal program. These results, along with those from our ongoing Phase 3 IGNITE 2 trial in complicated urinary tract infections (cUTI) which are expected in mid-2015, would form the basis of regulatory submissions seeking approval for eravacycline in both indications. We continue to target a New Drug Application submission to the FDA by the end of 2015.”

Tetraphase plans to submit the data from the Phase 3 IGNITE 1 clinical trial for presentation at a scientific meeting in 2015.

Conference Call Information

Tetraphase will host a conference call today at 4:30 pm Eastern Time to discuss the top-line data from the IGNITE 1 Phase 3 clinical trial. The call can be accessed by dialing (844) 831-4023 (U.S. and Canada) or (731) 256-5215 (international). To access the live audio webcast, or the subsequent archived recording, visit the “Investors Relations — Events & Presentations” section of the Tetraphase website at www.tphase.com. The webcast will be recorded and available for replay on the Tetraphase website for 30 days following the call.

About IGNITE 1

IGNITE 1 is a randomized, multi-center, double-blind, double-dummy, global Phase 3 clinical trial designed to assess the efficacy and safety of eravacycline, dosed intravenously 1.0 mg/kg every 12 hours, compared with ertapenem, dosed intravenously 1 g every 24 hours, in the treatment of cIAI. Per the trial design, 541 adult patients were enrolled in the trial in 66 centers worldwide. Under the guidance set by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the primary endpoint of the trial is clinical response at the test-of-cure (TOC) visit in the two treatment arms. For the FDA, the primary analysis is conducted using a 10% non-inferiority margin in the microbiological intent-to-treat (micro-ITT) population. For the EMA, the primary analysis is conducted using a 12.5% non-inferiority margin of the clinically evaluable patient population. Secondary endpoints include the microbiologic response in the treatment arms at the end of treatment, TOC and follow-up visits in the micro-ITT and microbiologically evaluable populations. The TOC visit takes place 25 to 31 days after the initial dose of eravacycline. The follow-up visit takes place 38 to 50 days after the initial dose of eravacycline.

About IGNITE 2

IGNITE 2 is a two-part, randomized, multi-center, double-blind, Phase 3 clinical trial designed to assess the efficacy and safety of eravacycline compared with levofloxacin in the treatment of cUTI at approximately 150 clinical trial sites worldwide. The two-part trial features a recently completed lead-in portion which was designed to determine the dose regimen to be carried forward into the pivotal portion of the trial. For the pivotal portion, 720 patients are expected to be enrolled and randomized 1:1 to receive eravacycline or levofloxacin (1.5 mg/kg intravenously every 24 hours followed by 200 mg orally every 12 hours) or levofloxacin (750 mg intravenously every 24 hours followed by 750 mg orally every 24 hours). This pivotal portion of the trial is designed to be a non-inferiority (10% margin) study. The primary endpoint for the FDA is the responder outcome (a combination of clinical cure rate and microbiological response) in the Microbiological Intent-to-Treat (micro-ITT) Population at the Post-Treatment visit (defined as 6-8 days after the completion of therapy). For the EMA, the primary endpoint is the microbiological response in the micro-MITT and microbiologically evaluable populations at the Post Treatment visit. Top-line results from the pivotal portion of the study are expected to be available in mid-2015.

About Eravacycline

Tetraphase’s lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Under this program, two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Eravacycline has been designated by the U.S. Food and Drug Administration as a Qualified Infectious Disease Product (QIDP) for both the cIAI and cUTI indications. This designation, which is assigned to qualifying new antibiotic product candidates, makes eravacycline eligible to benefit from certain development and commercialization incentives, including priority review, and eligibility for both fast-track status and an additional five years of U.S. market exclusivity.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Please visit www.tphase.com for more company information.

Forward-Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words “anticipates,” “believes,” “expects,” “plans,” “will” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether our cash resources will be sufficient to fund our continuing operations for the period we anticipate; whether the top line results from the lead in portion of IGNITE 2 will be predictive of the final results of the trial; whether eravacycline will advance through the clinical trial process on a timely basis or at all; whether enrollment for clinical trials will be achieved in the time frame expected; whether submissions will be made and approvals will be received from the United States Food and Drug Administration or equivalent foreign regulatory agencies on a timely basis or at all; whether, if eravacycline obtains approval, it will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of our most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2014. In addition, the forward-looking statements included in this press release represent our views as of December 17, 2014. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Investor:
Tetraphase
Teri Dahlman, 617-600-7040
tdahlman@tphase.com
or
Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com
or
Media:
Sam Brown Inc.
Mike Beyer, 773-463-4211
beyer@sambrown.com

(VOLC) To Be Acquired By Royal Philips (PHG)

Philips to acquire Volcano for USD 18.00 per share; total transaction value of USD 1.2 billion (approx. EUR 1 billion), inclusive of Volcano’s cash and debt – Agreement to acquire Volcano, a global leader in catheter-based imaging and measurement solutions for cardiovascular applications, advances Philips’ focused strategy in image guided therapy – Volcano provides proven clinical development and commercialization capabilities for Philips’ next generation of imaging and measurement technologies – Philips expects the transaction to accelerate sales growth as combined business is optimally positioned to address unmet needs in EUR 4 billion image-guided therapy market – Transaction expected to be accretive to Philips EPS by 2017 driven by revenue and cost synergies

AMSTERDAM and SAN DIEGO, Dec. 17, 2014 – Royal Philips (NYSE: PHG; AEX: PHIA) and Volcano Corporation (NASDAQ:VOLC), a global leader in catheter-based imaging and measurement solutions for cardiovascular applications, today announced that they have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Volcano for USD 18.00 per share, or a total equity purchase price of USD 1 billion (approx. EUR 800 million), to be paid in cash upon completion. The board of directors of Volcano has unanimously approved the transaction and recommends the offer to its shareholders. The transaction is expected to close in the first quarter of 2015.

In the last few years, Philips has created a leading image-guided therapy business through strategic investments in R&D, partnerships and technology licenses. Today, Philips has a rich portfolio of interventional imaging equipment, navigation tools, and services, and a sizeable global customer base, including each of the top 50 U.S. Heart Surgery and Cardiology hospitals. One in every three interventional X-ray systems sold globally is a Philips system. These systems provide the visual maps that allow the clinician to guide thin, tube-shaped instruments called catheters through the body, to the area of interest and perform the minimally invasive treatment.

In image-guided treatments of the heart and blood vessels, there is an increasing trend to use advanced catheters that are capable of producing ultrasound images of the interior of blood vessels (intravascular ultrasound or IVUS) or perform blood flow measurements (fractional flow reserve or FFR). There is a growing body of clinical evidence that the use of such technologies in conjunction with interventional X-ray helps improve procedural outcomes.

With 2013 sales of approximately USD 400 million, San Diego, California-based Volcano is a leader in catheter–based imaging and measurements for minimally invasive diagnostics and treatment of coronary artery disease and peripheral vascular disease. Volcano is the only company in the industry with a leading position in both IVUS imaging and FFR measurements. In addition, the company possesses the broadest product portfolio around these two technologies, a leading IP position and a nascent peripheral vascular therapeutics business that targets a segment with a double-digit growth rate.

The combination of two industry leaders will create new sources of recurring revenue streams and increase sales growth for Philips in the EUR 4 billion image-guided therapy market opportunity. Sales growth will be accelerated through Volcano’s close customer relationships associated with its disposable products and channel synergies that will create cross-selling opportunities between both companies’ existing customer bases. Furthermore, the combination of Volcano’s proven clinical development and commercialization capabilities with Philips’ next generation of imaging and measurement technologies, will allow Philips to introduce new solutions in higher growth segments such as the minimally invasive treatment of heart rhythm disorders and structural heart diseases. These are promising segments growing at double-digit rates.

“The agreement to acquire Volcano significantly advances our strategy to become the leading systems integrator in image-guided therapies,” said Frans van Houten, Chief Executive Officer of Royal Philips. “Volcano’s impressive and unique product portfolio is highly complementary to our strong offering in live image-guidance solutions, creating an opportunity to accelerate the revenue growth for our image-guided therapy business to a high single-digit rate by 2017. Our combined sales forces will be able to capture immediate cross selling opportunities, while our joint R&D teams will be able to develop new solutions to address significant unmet needs in the minimally invasive treatment of cardiovascular diseases.”

Mr. Van Houten added: “Image-guided therapies provide significant benefits for healthcare systems and patients, including reduced patient trauma, shorter recovery times and hospital stays, and lower costs. As a result, our clinical partners and customers are asking for a tighter integration of imaging and measurement technologies to enable such therapies. This transaction allows us to provide our customers with an integrated solution to improve procedural outcomes at a decisive stage in the health continuum.”

“I am very excited that Volcano will become part of Philips and join forces with its leading image guided therapy business,” said Scott Huennekens, Volcano President and Chief Executive Officer. “This transaction will be beneficial for our shareholders, customers, partners and employees. There is a large and growing global market opportunity for image-guided therapies, and as part of Philips, we gain the scale and resources needed to accelerate our goals of improving patient outcomes on a global basis, lowering cost and delivering innovative diagnostics and therapies in the coronary and peripheral markets. In addition, our shared expertise in the image-guided therapy market will allow us to further globalize our leading IVUS and FFR product offerings and enter new product areas.  We look forward to working closely with Philips and ensuring a smooth transition and closing.”

Upon completion of the transaction, the Volcano business and its 1,800 employees will be part of a dedicated, new image-guided therapy business group within Philips, which will be led by Philips executive Bert van Meurs, an experienced leader in the health care industry with a proven track record in the image-guided therapy market.

Financials
The acquisition will create a strategically and financially compelling combination that will provide higher growth, additional operating leverage through more productive sales operations, and enhance commercialization opportunities in new, adjacent segments. Philips will drive operational performance improvements through cost synergies and the implementation of proven productivity improvement methodologies such as Lean.  As a result, the transaction is expected to be accretive to Philips’ reported earnings per share by 2017, and Philips targets an EBITA margin for its image-guided therapy business group of around 20% by 2017.

The transaction is structured as a cash tender offer by Philips for all of the issued and outstanding shares of Volcano, to be followed by a merger in which each share of Volcano not tendered in the tender offer will be converted into the USD 18.00 per share price paid in the tender offer. Pursuant to the merger agreement, the transaction is subject to customary closing conditions, including certain regulatory clearances in the US and in certain non-US jurisdictions. The tender offer is not subject to any financing conditions. Philips intends to finance the acquisition through a combination of cash on hand and the issuance of debt.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 115,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

About Volcano Corporation
Through its multi-modality platform, Volcano is the global leader in intravascular imaging for coronary and peripheral therapeutic devices. The company’s broad range of technologies makes imaging and therapy simpler, more informative and less invasive and offers physicians and their patients around the world with industry-leading tools that aid diagnosis and guide and provide therapy. Founded in cardiovascular care and expanding into other specialties, Volcano is focused on improving patient and economic outcomes. For more information, visit the company’s website at www.Volcanocorp.com.

Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items, including without limitation completion of the tender offer and merger and any expected benefits of the merger, and certain forward-looking statements regarding Volcano, including without limitation with respect to its business, the proposed tender offer and merger, the expected timetable for completing the transaction, and the strategic and other potential benefits of the transaction. Completion of the tender offer and merger are subject to conditions, including satisfaction of a minimum tender condition and the need for regulatory approvals, and there can be no assurance that those conditions can be satisfied or that the transactions described in this release (the “Transactions”) will be completed or will be completed when expected. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “expects,” “expected,” “scheduled,” “estimates,” “intends,” “anticipates,” “projects,” “potential,” “continues” or “believes,” or variations of such words and phrases or state that certain actions, events, conditions, circumstances or results “may,” “could,” “should,” “would,” “might” or “will” be taken, occur or be achieved. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to, (i) the risk that not all conditions of the Offer or the merger will be satisfied or waived; (ii) uncertainties regarding the two companies’ ability to successfully market both new and existing products; (iii) uncertainties relating to the anticipated timing of filings and approvals relating to the Transactions; (iv) uncertainties as to the timing of the tender offer and merger; (v) uncertainties as to how many of Volcano’s stockholders will tender their stock in the tender offer; (vi) the possibility that competing offers will be made; (vii) the failure to complete the tender offer or the merger in the timeframe expected by the parties or at all; (viii) the outcome of legal proceedings that may be instituted against Volcano and/or others relating to the Transactions; (ix) Volcano’s ability to maintain relationships with employees, customers, or suppliers; (x) domestic and global economic and business conditions; (xi) developments within the euro zone; (xii) the successful implementation of Philips’ strategy and the ability to realize the benefits of this strategy; (xiii) legal claims; (xiv) changes in exchange and interest rates; (xv) changes in tax rates, raw materials and employee costs; (xvi) the ability to successfully exit certain businesses or restructure the operations; (xvii) the rate of technological changes; (xviii) political, economic and other developments in countries where Philips operates; (xix) industry consolidation and competition; and (xx) other risk factors described in Volcano’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the United States Securities and Exchange Commission (“SEC”). Any forward-looking statements in this release are based upon information known to Philips on the date of this announcement. Neither Philips nor Volcano undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Additional Information

The tender offer described in this communication (the “Offer”) has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Volcano or any other securities. On the commencement date of the Offer, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, will be filed with the SEC by Philips and a Solicitation/Recommendation Statement on Schedule 14D-9 will be filed with the SEC by Volcano. The offer to purchase shares of Volcano common stock will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. The tender offer statement will be filed with the SEC by Clearwater Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., which is a wholly owned subsidiary of Royal Philips, and the solicitation/recommendation statement will be filed with the SEC by Volcano. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the Offer, which will be named in the tender offer statement.

(BAGR) Grand Opening of Bagger Dave’s Burger Tavern in Birch Run, Michigan

SOUTHFIELD, Mich., Dec. 16, 2014  — Diversified Restaurant Holdings, Inc. (Nasdaq:BAGR) (“DRH” or the “Company”), the creator, developer and operator of the unique, full-service, ultra-casual restaurant and bar Bagger Dave’s Burger Tavern® (“Bagger Dave’s”) and one of the largest franchisees for Buffalo Wild Wings® (“BWW”), today announced the grand opening of a Bagger Dave’s in Birch Run, Michigan on Sunday, December 14, 2014, concurrent with the opening of a new co-located Buffalo Wild Wings. This opening marks the sixteenth Bagger Dave’s location in the state of Michigan.

The new Bagger Dave’s restaurant is located at 8827 Main Street and showcases refreshed interior and exterior design elements, including historical photos of the community as well an enclosed patio. The restaurant is located across from the Birch Run Premium Outlets, the largest outlet mall in the Midwestern United States.

“We are excited to have completed our development plans for 2014 with two restaurant openings in Birch Run. Their proximity to the largest and most frequently visited outlet mall in the Midwest makes for an ideal location and we believe that the prominent signage at the busy Interstate 75 exit should help generate strong traffic for both brands. We are particularly pleased to be introducing Bagger Dave’s high quality and differentiated menu offerings to Birch Run residents and visitors,” said Michael Ansley, President and CEO.

Regular restaurant hours will be Sunday and Monday, 11:00 AM to 10:00 PM, Tuesday through Thursday, 11:00 AM to 11:00 PM, and Friday and Saturday from 11:00 AM to 12:00 AM.

In 2014, DRH opened a total of nine new restaurants, including six Bagger Dave’s in Birch Run, Woodhaven, and Grand Blanc, Michigan; and Carmel, Fishers, and Schererville, Indiana; and three Buffalo Wild Wings in Birch Run, Michigan; Pinellas Park, Florida; and Hammond, Indiana.

About Diversified Restaurant Holdings

Diversified Restaurant Holdings, Inc. (Nasdaq:BAGR) (“DRH” or the “Company”) owns and operates Bagger Dave’s Burger Tavern, a full-service, family-friendly restaurant and full bar with a casual, comfortable atmosphere specializing in custom-built, proprietary, fresh prime rib recipe burgers, all-natural turkey burgers, hand-cut fries, locally crafted beers on draft, hand-dipped milk shakes, salads, black bean turkey chili, and much more. There are currently 24 company-owned Bagger Dave’s restaurants in Michigan and Indiana.  For more information, visit www.baggerdaves.com.

The Company also operates 42 Buffalo Wild Wings Grill & Bar franchised restaurants in Indiana, Illinois, Michigan, and Florida.

The Company routinely posts news and other important information on its website at www.diversifiedrestaurantholdings.com.

Safe Harbor Regarding Forward Looking Statements

The information made available in this news release contains forward-looking statements which reflect DRH’s current view of future events, results of operations, cash flows, performance, business prospects and opportunities. Wherever used, the words “anticipate,” “believe,” “expect,” “intend,” “plan,” “project,” “will continue,” “will likely result,” “may,” and similar expressions identify forward-looking statements as such term is defined in the Securities Exchange Act of 1934. Any such forward-looking statements are subject to risks and uncertainties and the Company’s actual growth, results of operations, financial condition, cash flows, performance, business prospects and opportunities could differ materially from historical results or current expectations. Some of these risks include, without limitation, the impact of economic and industry conditions, competition, food and drug safety issues, store expansion and remodeling, labor relations issues, costs of providing employee benefits, regulatory matters, legal and administrative proceedings, information technology, security, severe weather, natural disasters, accounting matters, other risk factors relating to our business or industry and other risks detailed from time to time in the Securities and Exchange Commission filings of DRH. Forward-looking statements contained herein speak only as of the date made and, thus, DRH undertakes no obligation to update or publicly announce the revision of any of the forward-looking statements contained herein to reflect new information, future events, developments or changed circumstances or for any other reason.

CONTACT: For more information contact:

         Investor Relations Contacts:
         Sheryl Freeman / Raphael Gross
         ICR Inc.
         646.277.1284 / 203.682.8253
         sheryl.freeman@icrinc.com / raphael.gross@icrinc.com

(IESC) Highlighted as a Top Workplace and Announces Recent Management Appointments

HOUSTON, Dec. 16, 2014  — Integrated Electrical Services, Inc. (or “IES”) (Nasdaq:IESC) today announced new divisional appointments and its ranking as a top workplace in Houston based on a survey conducted by the Houston Chronicle.

Recent Management Appointments

IES is pleased to announce several recent divisional appointments, including the hiring of Ed Zeuch as Vice President, Finance of the Infrastructure Solutions segment and Todd Lovell as Vice President, Program Director of the Commercial & Industrial segment. Additionally, IES’s Communications segment has added Robert Gosse as Branch Manager of its recently established Dallas, TX branch.

Mr. Zeuch has over 15 years of experience in finance and operations with companies including Schneider Electric, Teradata Corporation, and NCR Corporation. Over the last six years, Mr. Zeuch served as Chief Operating Officer at Carat Security Group.

Mr. Lovell has over 20 years of construction project management and most recently served as Senior Projects Manager for six years with Jacobs Engineering Group Inc. and five years with Tetra Tech, Inc. Mr. Lovell will be focused on driving strategic initiatives to ensure Commercial & Industrial’s continued growth and success.

James Lindstrom, Chairman and Chief Executive Officer, continued, “We believe the strong new additions to our team validate IES as an employer of choice and our ability to attract the best employees possible. We remain committed to developing our employees and investing in talent to expand our capabilities and support our growth and backlog in 2015.”

Top Workplace by the Houston Chronicle

IES has been named a Top Workplace by the Houston Chronicle, placing second in the ranking of midsize businesses. The second place ranking is an improvement of 13 spots from a 15^th-place ranking in 2013. The ranking is based on an annual survey of employees conducted for the Houston Chronicle by the research firm WorkplaceDynamics.

Sarah Kerrigan, head of Human Resources at IES, stated, “We are honored to be recognized as one of the top places to work in Houston. The results of these independent surveys confirm that our focus on creating an ownership mindset for all employees and developing an entrepreneurial environment differentiates IES.”

ABOUT INTEGRATED ELECTRICAL SERVICES, INC.

Integrated Electrical Services, Inc. is a holding company that owns and manages diverse operating subsidiaries, comprised of providers of industrial products and infrastructure services to a variety of end markets. Our 2,700 employees serve clients in the United States and abroad. For more information about IES, please visit www.ies-co.com.

Certain statements in this release may be deemed “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, all of which are based upon various estimates and assumptions that the Company believes to be reasonable as of the date hereof. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “seek,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology. These statements involve risks and uncertainties that could cause the Company’s actual future outcomes to differ materially from those set forth in such statements. Such risks and uncertainties include, but are not limited to, the ability of our controlling shareholder to take action not aligned with other shareholders; the sale or disposition of the shares of our common stock held by our controlling shareholder, which, under certain circumstances, would trigger change of control provisions in our severance plan or financing and surety arrangements; or any other substantial sale of our common stock, which could depress our stock price; relatively low liquidity levels of our common stock, which could depress our stock price; the possibility that we issue additional shares of common stock or convertible securities that will dilute the percentage ownership interest of existing stockholders and may dilute the book value per share of our common stock; the possibility that certain tax benefits of our net operating losses may be restricted or reduced in a change in ownership; the inability to carry out plans and strategies as expected, including our inability to identify and complete acquisitions that meet our investment criteria in furtherance of our corporate strategy; limitations on the availability of sufficient credit or cash flow to fund our working capital needs and capital expenditures and debt service; difficulty in fulfilling the covenant terms of our credit facilities; competition in the industries in which we operate, both from third parties and former employees, which could result in the loss of one or more customers or lead to lower margins on new projects; challenges integrating new businesses into the Company or new types of work, products or processes into our segments; fluctuations in operating activity due to downturns in levels of construction, seasonality and differing regional economic conditions; a general reduction in the demand for our services; a change in the mix of our customers, contracts or business; our ability to enter into, and the terms of, future contracts; our ability to successfully manage projects; the possibility of errors when estimating revenue and progress to date on percentage-of-completion contracts; closures or sales of facilities resulting in significant future charges, including potential warranty losses or other unexpected liabilities, or a significant disruption of our operations; inaccurate estimates used when entering into fixed-priced contracts; the cost and availability of qualified labor; an increased cost of surety bonds affecting margins on work and the potential for our surety providers to refuse bonding or require additional collateral at their discretion; increases in bad debt expense and days sales outstanding due to liquidity problems faced by our customers; the recognition of potential goodwill, long-lived assets and other investment impairments; credit and capital market conditions, including changes in interest rates that affect the cost of construction financing and mortgages, and the inability for some of our customers to retain sufficient financing which could lead to project delays or cancellations; accidents resulting from the physical hazards associated with our work and the potential for accidents; our ability to pass along increases in the cost of commodities used in our business, in particular, copper, aluminum, steel, fuel and certain plastics; potential supply chain disruptions due to credit or liquidity problems faced by our suppliers; loss of key personnel and effective transition of new management; success in transferring, renewing and obtaining electrical and construction licenses; backlog that may not be realized or may not result in profits; uncertainties inherent in estimating future operating results, including revenues, operating income or cash flow; disagreements with taxing authorities with regard to tax positions we have adopted; the recognition of tax benefits related to uncertain tax positions; complications associated with the incorporation of new accounting, control and operating procedures; the possibility that our internal controls over financial reporting and our disclosure controls and procedures may not prevent all possible errors that could occur; the effect of litigation, claims and contingencies, including warranty losses, damages or other latent defect claims in excess of our existing reserves and accruals; growth in latent defect litigation in states where we provide residential electrical work for home builders not otherwise covered by insurance; the possibility that our current insurance coverage may not be adequate or that we may not be able to obtain a policy at acceptable rates; future capital expenditures and refurbishment, repair and upgrade costs, and delays in and costs of refurbishment, repair and upgrade projects; and liabilities under laws and regulations protecting the environment.

You should understand that the foregoing, as well as other risk factors discussed in this document and in the Company’s annual report on Form 10-K for the year ended September 30, 2014, could cause future outcomes to differ materially from those experienced previously or those expressed in such forward-looking statements. The Company undertakes no obligation to publicly update or revise any information, including information concerning its controlling shareholder, net operating losses, borrowing availability, or cash position, or any forward-looking statements to reflect events or circumstances that may arise after the date of this release.

Forward-looking statements are provided in this press release pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995 and should be evaluated in the context of the estimates, assumptions, uncertainties, and risks described herein.

General information about Integrated Electrical Services, Inc. can be found at http://www.ies-co.com under “Investors.” The Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, as well as any amendments to those reports, are available free of charge through the Company’s website as soon as reasonably practicable after they are filed with, or furnished to, the SEC.

CONTACT: Robert Lewey, CFO
         Integrated Electrical Services, Inc.
         713-860-1500

(BLRX) Teams Up With Novartis (NVS) In Strategic Collaboration

Global pharmaceutical company makes initial $10 million equity investment in BioLineRx – – BioLineRx to host conference call today, December, 16 at 10:00 a.m. EST

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has entered into a multi-year strategic collaboration agreement with Novartis Pharma AG designed to facilitate development and commercialization of Israeli-sourced drug candidates.

Leveraging BioLineRx’s close and long-lasting ties with academic institutions, hospitals and biomedical companies in Israel, as well as its proven project screening process and development expertise, Novartis will evaluate projects identified and presented by BioLineRx for co-development and potential future licensing under the collaboration. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept. As part of the agreement, Novartis has made an initial equity investment in BioLineRx of $10 million for 12.8% of BioLineRx’s current shares outstanding.

Dr. Kinneret Savitsky, CEO of BioLineRx, said, “This is a transformative collaboration for BioLineRx. Recognition by Novartis, the global leader for innovative therapeutics, is a further validation of our drug development capabilities, our business model, and our strong track record of selecting the most promising innovative therapeutic programs stemming from Israel’s leading research institutions and biotech start-ups, and developing them towards commercialization. Working closely with Novartis at relatively early stages of project development will enable us to tailor our development processes to meet their needs and expectations, helping to ensure agreed upon clinical goals are met successfully.”

Under the terms of the agreement, Novartis acquired an initial 5,000,000 American Depositary Shares of BioLineRx in a private transaction at a price of $2.00 per share for a total equity investment of $10 million. Novartis will not have any governance rights and has agreed to certain standstill provisions. Novartis and BioLineRx will jointly evaluate both clinical and pre-clinical stage projects presented by BioLineRx via a Joint Steering Committee, which will determine which projects to advance further in development and on what terms. Projects at or reaching the clinical stage will be eligible for selection by Novartis. Upon selection of a project, Novartis will pay BioLineRx an option fee of $5 million, as well as fund 50% of the anticipated remaining development costs associated with establishing clinical proof-of-concept, in the form of an additional equity investment in BioLineRx. Novartis will have an exclusive right of first negotiation to license from BioLineRx each selected project upon establishment of clinical proof-of-concept. The companies intend to develop up to three programs pursuant to this collaboration.

Conference Call and Webcast Information

BioLineRx will hold a conference call today, December 16, 2014, at 10:00 a.m. EST. Dr. Kinneret Savitsky, Chief Executive Officer; Philip Serlin, Chief Financial and Operating Officer; and David Malek, Vice-President of Business Development, will present and provide more details on the collaboration with Novartis. To access the conference call, please dial 1-888-668-9141 from the U.S. or +972-3-918-609 internationally. The call will also be available via live webcast through BioLineRx’s website. A replay of the conference call will be available approximately two hours after completion of the live conference call. To access the replay, please dial 1-888-326-9310 from the U.S. or +972-3-925-5901 internationally. The replay will be available through December 19, 2014.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial; BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML) as well as a Phase 1 study for stem cell mobilization; and BL-7010 for celiac disease, which has completed a Phase 1/2 study.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.

Safe Harbor Statement

Various statements in this release concerning BioLineRx’s future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 17, 2014. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

(MRVC) Board Authorizes $8 Million Share Repurchase Plan

MRV Communications (NASDAQ:MRVC), a global provider in converged packet and optical solutions that empower the optical edge and network integration services for leading communications service providers, announced MRV‘s Board of Directors has authorized a share repurchase program for up to $8 million.

The stock repurchase program will be operated in accordance with the requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In connection therewith, MRV is entering into a stock repurchase plan under Rule 10b5-1 of the Exchange Act to facilitate the repurchase of its Common Stock. Purchases of Common Stock will be subject to terms set forth in the Rule 10b5-1 plan and certain price, volume and timing constraints. Accordingly, there can be no assurance as to how many shares will be purchased.

The plan expires on November 13, 2015 or may be suspended or discontinued at any time, without prior notice. The funding for the repurchase is available from existing cash on hand. A plan under Rule 10b5-1 of the Exchange Act allows a company to repurchase its shares at times when it otherwise might be prevented from doing so under insider trading laws or because of self-imposed trading blackout periods. A broker selected by MRV will have the authority under the terms and limitations specified in the plan to repurchase shares on MRV’s behalf in accordance with the terms of the plan.

About MRV Communications

MRV Communications is a global provider in converged packet and optical solutions that empower the optical edge and network integration services for leading communications service providers. For more than two decades, the most demanding service providers, Fortune 1000 companies and governments worldwide have trusted MRV to provide best-in-class solutions and services for their mission-critical networks. We help our customers overcome the challenge of orchestrating the ever-increasing need for capacity while improving service delivery and lowering network costs for critical applications such as cloud connectivity, high-capacity business services, mobile backhaul and data center connectivity. For more information please visit www.mrv.com.

Forward Looking Statements

This press release may contain statements regarding future financial and operating results of MRV, management’s assessment of business trends, and other statements about management’s future expectations, beliefs, goals, plans or prospects and those of the market segments in which MRV is engaged that are based on management’s current expectations, estimates, forecasts and projections about MRV and its consolidated businesses and the respective market segments in which MRV’s businesses operate, in addition to management’s assumptions. Statements in this press release regarding MRV’s future financial and operating results, which are not statements of historical facts, constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as “expects,” “anticipates,” “envisions,” “estimates,” “targets,” “intends,” “plans,” “believes,” “seeks,” “should,” “could,” “forecasts,” “projects,” variations of such words and similar expressions, are intended to identify such forward-looking statements which are not statements of historical facts. These forward-looking statements are not guarantees of future performance nor guarantees that the events anticipated will occur or expected conditions will remain the same or improve. These statements involve certain risks, uncertainties and assumptions, the likelihood of which are difficult to assess and may not occur, including risks that each of its business segments may not make the expected progress in its respective market, or that management’s long-term strategy may not achieve the expected results. Therefore, actual outcomes, performance and results may differ from what is expressed or forecast in such forward-looking statements, and such differences may vary materially from current expectations.

For further information regarding risks and uncertainties associated with MRV’s businesses, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of MRV’s SEC filings, including, but not limited to its annual report on Form 10-K for the year ended December 31, 2013, copies of which may be obtained by contacting MRV’s investor relations department or by visiting MRV’s website at http://www.mrv-corporate.com or the SEC’s EDGAR website at http://www.sec.gov.

(ATEA) Receives Positive NASDAQ Listing Determination

HORSHAM, Pa., Dec. 16, 2014  — Astea International Inc. (ATEA), the leader in service management and mobile workforce solutions, announced today that it has received a positive determination from the NASDAQ Listings Qualifications Panel (the “Panel”) advising it that the Company has been provided a further extension of time, subject to certain conditions, through March 16, 2015, to evidence compliance with the $2.5 million stockholders’ equity requirement for continued listing on The NASDAQ Capital Market. The Company is working to timely evidence compliance with the terms of the Panel’s decision; however, there can be no assurance that it will be able to do so.

About Astea International

Astea International (NASDAQ: ATEA) is a global provider of software solutions that offer all the cornerstones of service lifecycle management, including customer management, service management, asset management, forward and reverse logistics management and mobile workforce management and optimization. Astea’s solutions link processes, people, parts, and data to empower companies and provide the agility they need to achieve sustainable value in less time, and successfully compete in a global economy. Since 1979, Astea has been helping more than 600 companies drive even higher levels of customer satisfaction with faster response times and proactive communication, creating a seamless, consistent and highly personalized experience at every customer relationship touch point.

www.astea.com.   Service Smart.  Enterprise Proven.

© 2014 Astea International Inc. Astea and Astea Alliance are trademarks of Astea International Inc.  All other company and product names contained herein are trademarks of the respective holders.

Forward-looking Statements

Statements in this press release, other than statements of historical information, are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks which may cause the Company’s actual results in future periods to differ materially from expected results. Those risks include, among others, risks associated with increased competition, customer decisions, the successful completion of continuing development of new products, the successful negotiations, execution and implementation of anticipated new software contracts, the successful addition of personnel in technical areas, our ability to complete development and sell and license our products at prices which result in sufficient revenues to realize profits and other business factors beyond the Company’s control. These and other risks are described in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to the Company’s Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q.

(SYRG) Announces Closing on Acquisition of Wattenberg Field Assets

(NVGN) Announces Breakthrough Discovery in the Treatment of Melanoma

SYDNEY, Dec. 16, 2014  — Novogen Limited (ASX:NRT; NASDAQ:NVGN), Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

The Company believes this is an important breakthrough discovery for two reasons. The first is that it confirms that TRXE-009 is an important new potential treatment for melanoma, including for the treatment of secondary brain cancers due to melanoma, for which there currently are no effective therapies. The second is that it offers evidence for the first time of an hypothesized link between brain cancer and melanoma.

The link has long been considered a possibility because nerve cells and melanocytes (the melanin pigment-bearing cells in skin that lead to melanoma) have a common origin in the embryo known as the neural crest. This primitive tissue gives rise to the neural cells that go on to form the brain, spinal cord, and peripheral nerves, as well as cells that form the structures of the skull; melanocytes also come from this embryonic tissue. Up till now, no functional link has been found between brain cells and melanocytes, or between brain cancer and melanoma. TRXE-009 is the first compound to demonstrate the possibility of a common link, suggesting that is the first drug with the ability to identify cancers arising in cells that have the neural crest as their common origin.

TRXE-009 has been confirmed as a potential new treatment for both adult and paediatric neural cancers. TRXE-009 previously has been announced as a world-first in having exceptionally high killing activity against adult brain cancer (glioblastoma multiforme) stem cells, and against the paediatric brain cancers – medulloblastoma and DIPG (diffuse interstitial pontine glioma) – all tumors that are highly resistant to known chemotherapies. That same high potency is now confirmed against melanoma cells, with activity unaffected by the tumor’s BRAF gene status.

Dr Graham Kelly, Novogen Group CEO, said, “This latest finding brings the value of TRXE-009 into true perspective for us. We initially developed the compound for brain cancer. We saw it as the first chemotherapy with the potential to make a meaningful difference to the survival prospects of patients, both adult and children, with primary brain cancer.”

“From there we looked at its ability to kill other cancers of neural origin, and discovered that the same potency against brain cancer cells extended to neuroblastoma cells, a potential deadly cancer in children that arises in peripheral nerve tissue outside of the brain.”

“With the realisation that we arguably had the first anti-cancer drug capable of recognising cancers arising in tissues with a common neural crest origin, it was an obvious next step to look at melanoma, with the outcome that we are announcing today,” Kelly explained.

Novogen will be delivering TRXE-009 as a proprietary construct known as Trilexium. Trilexium has been developed to maximise the bio-availability of the drug to cancer cells in the body. Animal xenograft studies of human cancer have confirmed the efficacy of Trilexium.

Kelly said, “This finding completely changes the outlook for this drug candidate. From a drug that was due to come into the clinic specifically for the treatment of adult and childhood neural cancers, we now are presented with a prospective treatment for malignant melanoma, including the treatment of secondary brain cancers due to melanoma for which there currently is no effective therapy.”

“We naturally are keen to bring Trilexium into the clinic as soon as possible,” said Kelly. “But our entire focus at the moment in terms of a clinical program is the product candidate, Cantrixil. That is where our efforts are centred and where our current financial resources are committed, with the objective of achieving the key inflection point of transiting into a clinical-stage company as a firm strategy. Trilexium will enter the clinic only when we have been successful in raising funds specifically ear-marked for this project. Those discussions are current with interested stakeholders.”

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial disintegration.

The ATM compounds target the micro-filament component of the cancer cell’s cytoskeleton and have been designed to combine with anti-microtubular drugs (taxanes, vinca alakaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate (‘Anisina’).

About TRXE-009

TRXE-009 is an SBP compound generated by the Company’s VAL-ID (Versatile Approach to Library-based Iterative Design) drug discovery process, with structure-activity relationship driving design based on activity against brain cancer stem cells and the known required chemical criteria to facilitate passage across the blood-brain barrier.

About Trilexium

Trilexium is a construct of drug candidate, TRXE-009, in a proprietary oil-based formulation selected for its ability to maximize passage of drug across the cancer cell plasma membrane.

About Melanoma

Malignant melanoma (Stage 4), where the cancer has spread away from the site of origin, remains a major unmet clinical need with limited effective treatment options. Main sites of metastasis are lungs, liver, brain, bones, and distant lymph nodes and skin. Immunotherapies (ipilumumab, vemurafenib, vaccines), chemotherapy (dacarbazine, vinblastine), radiotherapy and surgery are used to prolong life in Stage 4 disease, but these modalities provide little benefit where metastases has occurred to the brain.

Further information is available on our websites www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly
Executive Chairman & CEO Novogen Group
Graham.Kelly@novogen.com
+61-2-9472-4100

Media Enquiries

Cristyn Humphreys
Operations Manager Novogen Group
Cristyn.Humphreys@novogen.com
+61-2-9472-4111

(ISIG) Announces Preliminary Expectations for Fourth Quarter 2014 Results

Insignia Systems, Inc. (Nasdaq:ISIG) (“Insignia” or “the Company”) today provided certain preliminary information regarding its expected financial results for the fourth quarter of 2014. As discussed in Insignia’s press release, dated October 29, 2014, announcing financial results for the third quarter of 2014 (the “third quarter 2014 release”), the Company’s business currently faces increasing challenges in the market, driven primarily by recent overall cost reduction efforts among consumer packaged goods (CPG) manufacturers and changes in promotional spending by two of the Company’s larger CPG customers. In the third quarter release, the Company disclosed that, as of the date of that release, its year-over-year bookings for the fourth quarter of 2014 were down by approximately 12%. Insignia now expects net sales for the fourth quarter of 2014 will range from $5.8 million to $6.1 million, down 12% to 16% compared to the fourth quarter of 2013. Given the Company’s investments in sales and marketing thus far in 2014 to sustain and grow Insignia’s core products and launch The Like Machine™, the Company now expects a net loss for the fourth quarter of 2014 ranging from $300,000 to $500,000, including certain restructuring costs described below. Fourth quarter 2014 expected results are preliminary and are subject to the Company’s management and independent auditor completing their customary closing and audit procedures following the quarter, among other factors.

A restructuring plan has been approved and will be implemented to reduce costs moving forward. The Company anticipates a pre-tax restructuring charge of approximately $130,000, primarily consisting of an office lease reserve, which will be reflected in its fourth quarter 2014 results. Current backlog for programs running in 2015 is $8.3 million, while the backlog one year ago for programs running in 2014 was $7.4 million.

Glen Dall, President and CEO, commented, “We are disappointed in our fourth quarter 2014 results. While we are encouraged by the increase in backlog, it is too early to predict 2015 sales levels. Moving forward, we are committed to aligning our expenses to revenue, while continuing efforts to grow our core business, and successfully launch The Like Machine. We have confidence in our team and remain dedicated to focusing on delivering long-term value.”

About Insignia Systems, Inc.

Insignia Systems, Inc. is a developer and marketer of innovative in-store products, programs, and services that help consumer goods manufacturers and retail partners drive sales at the point of purchase. Insignia provides at-shelf media solutions in approximately 13,000 retail supermarkets, 2,000 mass merchants and 8,000 dollar stores. With a client list of over 200 major consumer goods manufacturers, including General Mills, Kellogg Company, Kraft Foods, Nestlé, and P&G, Insignia helps major brands deliver on their key engagement, promotion, and advertising objectives right at the point-of-purchase. For additional information, contact (888) 474-7677, or visit the Insignia website at www.insigniasystems.com.

Cautionary Statement for the Purpose of Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995

Statements in this press release which are not statements of historical or current facts are considered forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. The words “believes,” “expects,” “anticipates,” “seeks” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these or any forward-looking statements, which speak only as of the date of this press release. Statements made in this press release regarding, for instance: current expectations as to fourth quarter 2014 or future financial performance; backlog; ability to implement and achieve benefits from restructuring efforts; benefits of sales and marketing investments; and ability to sustain and grow core products and launch new products, are forward-looking statements. These forward-looking statements are based on current information, which we have assessed and which by its nature is dynamic and subject to rapid and even abrupt changes. As such, actual results may differ materially from the results or performance expressed or implied by such forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, including: (i) the risk that management may be unable to fully or successfully implement its business plan, including restructuring efforts, to achieve and maintain profitability in the future; (ii) the risk that backlog will not result in actual sales; (iii) the risk that the Company will not be able to sustain and grow core product offerings or to develop, implement and grow new product offerings in a successful manner, including our ability to gain retailer acceptance of new product offerings; (iv) the unexpected loss of a major consumer packaged goods manufacturer relationship or retailer agreement or termination of our relationship with News America; (v) prevailing market conditions in the in-store advertising industry, including intense competition for agreements with retailers and consumer packaged goods manufacturers and the effect of any delayed or cancelled customer programs; (vi) potentially incorrect assumptions by management with respect to the financial effect of cost containment or reduction initiatives, current strategic decisions, current sales trends for fiscal year 2015; and (vi) other economic, business, market, financial, competitive and/or regulatory factors affecting the Company’s business generally, including those set forth in our Annual Report on Form 10-K for the year ended December 31, 2013 and additional risks, if any, identified in our Quarterly Reports on Form 10-Q and our Current Reports on Forms 8-K filed with the SEC. Such forward-looking statements should be read in conjunction with the Company’s filings with the SEC. The Company assumes no responsibility to update the forward-looking statements contained in this press release or the reasons why actual results would differ from those anticipated in any such forward-looking statement, other than as required by law.

Insignia Systems, Inc.
John Gonsior, 763-392-6200
CFO